Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Coronavirus: diagnóstico y terapia en humanos

Resultados 149 resultados
LastUpdate Última actualización 04/07/2025 [07:25:00]
pdfxls
Solicitudes publicadas en los últimos 60 días/Published applications in the last 60 days
Resultados 1 a 149  

A MULTI-ANTIGENIC RNA SARS-COV-2 VACCINE AND ASSOCIATED METHODS

NºPublicación:  AU2023395159A1 03/07/2025
Solicitante: 
GENEIUS BIOTECHNOLOGY INC
GENEIUS BIOTECHNOLOGY, INC
AU_2023395159_PA

Resumen de: AU2023395159A1

The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS AND METHODS

NºPublicación:  EP4577239A1 02/07/2025
Solicitante: 
CAPRICOR INC [US]
Capricor, Inc
CN_120166938_PA

Resumen de: AU2023329395A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

NºPublicación:  SI4230650T1 30/06/2025
Solicitante: 
RQBIO COVID LTD [GB]
RQBio Covid Limited
SI_4230650_T1

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

SARS-COV-2 SUBUNIT VACCINE

NºPublicación:  ES3030310T1 27/06/2025
Solicitante: 
HIPRA SCIENT S L U
LABORATORIOS HIPRA S A
Hipra Scientific, S.L.U,
Laboratorios Hipra S.A
US_2024316183_PA

Resumen de: US2024316183A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS

NºPublicación:  WO2025137284A2 26/06/2025
Solicitante: 
THE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

Resumen de: WO2025137284A2

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

RESPIRATORY TRACT INFECTION THERAPEUTICS AGAINST COVID-19

NºPublicación:  US2025207140A1 26/06/2025
Solicitante: 
CITY OF HOPE [US]
APTERNA LTD [GB]
City of Hope,
Apterna Limited
WO_2023183820_PA

Resumen de: US2025207140A1

Provided herein, inter alia, are compositions comprising nucleic acid compounds and methods of using the compositions for the prevention and treatment of respiratory diseases, including SARS-CoV-2 infections.

T CELL-BASED SARS-COV-2 VACCINE

NºPublicación:  WO2025137448A1 26/06/2025
Solicitante: 
GEORGIA STATE UNIV RESEARCH FOUNDATION INC [US]
LOYOLA UNIV CHICAGO [US]
DU LANYING [US]
SHI JUAN [US]
QIAO LIANG [US]
COMPAS RYAN [US]
GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC,
LOYOLA UNIVERSITY CHICAGO,
DU, Lanying,
SHI, Juan,
QIAO, Liang,
COMPAS, Ryan

Resumen de: WO2025137448A1

The present disclosure relates to coronavirus vaccines and methods for use thereof.

SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES

NºPublicación:  WO2025137577A1 26/06/2025
Solicitante: 
THE JOHNS HOPKINS UNIV [US]
HEIDELBERG BIOLABS GMBH [DE]
THE JOHNS HOPKINS UNIVERSITY,
HEIDELBERG BIOLABS GMBH

Resumen de: WO2025137577A1

Provided herein are short viral RNA (svRNA) and human RNA sequences that exhibit modulated expression during viral infection and are therefore useful for detecting viral infections. Further disclosed herein are compositions, methods, and kits for detecting and treating infections, including early-stage and latent infections with low viral titers. In certain embodiments the compositions, methods, and kits for detecting and treating infections include detecting in a sample from a subject 10-50 nucleotide length short viral RNA (svRNA), modulated expression of 10-50 nucleotide length RNA in the subject, or a combination thereof, thereby detecting infection by a virus in the subject.

SARS-COV-2 SUBUNIT VACCINE

NºPublicación:  ES3030145T1 26/06/2025
Solicitante: 
HIPRA SCIENT S L U
LABORATORIOS HIPRA S A
Hipra Scientific, S.L.U,
Laboratorios Hipra S.A
US_2025186576_PA

Resumen de: US2025186576A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

METHODS AND COMPOSITIONS FOR INHIBITING VIRAL METHYLTRANSFERASES

NºPublicación:  US2025205178A1 26/06/2025
Solicitante: 
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
WO_2024054941_PA

Resumen de: US2025205178A1

SARS-CoV-2 has caused a global pandemic with significant humanity and economic loss since the beginning of 2020. Flaviviruses such as Zika and Dengue viruses are also significant human pathogens. Although SARS-CoV-2 vaccines are effective in preventing severe disease outcomes, they are less effective in controlling infection or re-infection, particularly due to rapid evolution of viral variants of SARS-CoV-2. Currently only limited options are available to treat SARS-CoV-2 and flavivirus infections for vulnerable populations. Potential of a future pandemic of other viruses is high. The present invention features compositions and methods for a universal high throughput screening (HTS) assay to identify inhibitors targeting the S-adenosyl-L-methionine (SAM)-binding site of viral methyltransferases (MTases) using SAM as a methyl donor.

PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS

NºPublicación:  US2025206754A1 26/06/2025
Solicitante: 
MICAR INNOVATION LTD [BG]
\"Micar Innovation\" LTD
BG_113517_A

Resumen de: US2025206754A1

A chemical compound 2-({6-phenylthieno2,3-dpyrimidin-4-yl}oxy)benzamide for use as a CCR7 (C-C chemokine receptor type 7) antagonist. It is also a pan-chemokine antagonist and has an antagonistic effect to CCR1, CCR2, CCR3, CCR5, CCR9 and CXCR4 chemokine receptors for use in the prevention of metastatsis formation in lung, liver and ribs in in vivo mice breast cancer model. Also described are chemical compounds 3-chloro-2-{6-(2-chlorophenyl)-2,5-dimethylthieno2,3-dpyrimidin-4-yloxy}benzamide and 3-chloro-2-{6-(2-chlorophenyl)-2-methylthieno2,3-dpyrimidin-4-yloxy}benzamide, as pan-chemokine antagonists. These compounds are for use in the prevention or treatment of: (i) diseases associated with chemokine receiptors which are, specifically, lung, liver, ribs and lymph node metastasis and the progression of many different malignancies such as breast, gastric, skin (melanoma), head and neck, lung, esophageal, hepatocellular, cervical, thyroid, tonsillar, colorectal and prostate cancers; (ii) virus infection diseases associated with chemokine receptors such as HIV-1, HIV-2, SARS-CoV-2 (COVID-19); and (iii) the immune related diseases such as psoriasis, arthritis and atopic demiatitis.

TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES

NºPublicación:  US2025205268A1 26/06/2025
Solicitante: 
MERCK SHARP & DOHME LLC [US]
EMORY UNIV [US]
MERCK SHARP & DOHME LLC,
EMORY UNIVERSITY

Resumen de: US2025205268A1

Therapies comprising administering at least one antiviral nucleoside, and the use of such therapies in the treatment of viral infections, such as infection by Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, orthomyxoviridae virus, paramyxoviridae virus, RSV, influenza A virus, influenza B virus, filoviridae virus, human coronavirus, SARS-CoV-1, MERS-CoV, SARS-CoV-2, Ebola virus, or Zika virus, are disclosed herein.

ANTIVIRAL COMPOSITION COMPRISING CHITOSAN AND XANTHOHUMOLONE

NºPublicación:  US2025205273A1 26/06/2025
Solicitante: 
HEALTH PLUS [FR]
HEALTH PLUS
WO_2023186804_A1

Resumen de: US2025205273A1

The present invention relates to a composition comprising at least chitosan and xanthohumolone, to a process for preparing same and to the uses thereof. More particularly, the invention relates to a composition comprising at least chitosan and xanthohumolone for use as an antiviral composition, in particular in the treatment or prevention of COVID-19.

PEPTIDES, NUCLEIC ACIDS, RECOMBINANT EXPRESSION VECTORS, CELLS, SARS-COV-2 VACCINE SUBSTANCE, SARS-COV-2 VACCINE COMPOSITION, AND SARS-COV-2 IMMUNIZATION METHOD

NºPublicación:  WO2025135605A1 26/06/2025
Solicitante: 
UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: WO2025135605A1

Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.

BIOMARKERS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF NEUROLOGICAL POST ACUTE SEQUELAE OF COVID 19 (NPASC)

NºPublicación:  EP4573370A1 25/06/2025
Solicitante: 
PERCHERON THERAPEUTICS LTD [AU]
Percheron Therapeutics Ltd
AU_2023326053_PA

Resumen de: AU2023326053A1

Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.

COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE

NºPublicación:  ZA202401786B 25/06/2025
Solicitante: 
AIM IMMUNOTECH INC [US]
AIM IMMUNOTECH INC
US_2024350527_A1

Resumen de: ZA202401786B

Disclosed is a method for treating a subject that has previously been infected with SARS-CoV-2 and exhibiting at least one Post COVID- 19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

Diagnostic testing apparatus and system

NºPublicación:  GB2636672A 25/06/2025
Solicitante: 
RAPID VIRAL DETECTION SYSTEMS LLC [US]
Rapid Viral Detection Systems LLC
GB_2636672_PA

Resumen de: GB2636672A

A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.

ALOTAKETAL COMPOUNDS AND DERIVATIVES THEREOF FOR USE AS ANTIVIRAL AGENTS

NºPublicación:  US2025195464A1 19/06/2025
Solicitante: 
THE UNIV OF BRITISH COLUMBIA [CA]
THE UNIVERSITY OF BRITISH COLUMBIA
US_2025195464_A1

Resumen de: US2025195464A1

Provided herein are Alotaketal compounds and derivatives thereof that have antiviral activity. In particular, the invention relates to a subset of compounds represented by Formulas (1), (2) and (3), for use as antiviral agents in the treatment or prevention of coronavirus infection. Methods for using the compounds in the treatment or prophylaxis of a coronavirus infection are provided. In particular, the coronavirus infection may selected from one or more of the following: Severe Acute Respiratory Syndrome (SARS) coronavirus-1 (SARS-C0V-1) infection; SARS coronavirus-2 (SARS-C0V-2) infection; and Middle East Respiratory Syndrome (MERS) coronavirus (MERS-CoV) infection. More specifically, the coronavirus infection may be a human coronavirus 229E (HC0V-229E) infection.

ANTI-HUMAN CORONAVIRUS COMPOSITION

NºPublicación:  US2025195557A1 19/06/2025
Solicitante: 
MEIJI CO LTD [JP]
Meiji Co., Ltd
US_2025195557_A1

Resumen de: US2025195557A1

An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).

METHOD AND BIOMARKER FOR PREDICTING SEVERITY OF COVID-19 DISEASE AND METHOD FOR THERAPEUTIC INTERVENTION IN COVID-19 DISEASE

NºPublicación:  US2025201406A1 19/06/2025
Solicitante: 
UNIV OF CENTRAL FLORIDA RESEARCH FOUNDATION INC [US]
University of Central Florida Research Foundation, Inc
WO_2023147176_PA

Resumen de: US2025201406A1

Method for predicting severity of COVID-19 disease resulting from infection with SARS-COV-2 (severe acute respiratory syndrome coronavirus 2). The method uses a high dimensional approach to construct a comprehensive metabolic landscape of immune cells participating in the anti-viral response against SARS-CoV-2. Also encompassed within the invention are novel immune cell subsets exhibiting metabolic dysfunction that could serve as predictive biomarkers for COVID-19 severity or as targets for therapeutic interventions in COVID-19 disease.

MULTI-EPITOPE MRNA SARS-COV-2 VACCINE FOR BOOSTING IMMUNITY THROUGH THE ACTIVATION OF CD4 AND CD8 T CELLS AS WELL AS B LYMPHOCYTES

NºPublicación:  US2025195639A1 19/06/2025
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
US_2025195639_A1

Resumen de: US2025195639A1

In various embodiments immunogenic nanoparticles are provided that are capable of raising an immune response directed against SARS-CoV-2. In certain embodiments the immunogenic nanoparticles comprise mRNA multi-epitope vaccines that can be used in combination with or independent of other covid-19 vaccines (e.g., the spike protein mRNA vaccine(s)) to invoke a strong CD8+ or CD4+ T-cell as well as neutralizing antibody producing B-cell responses. In certain embodiments this vaccine is based on the rational combination of well-conserved T- and B-cell epitopes identified COVID-19 and viral variants.

STABILIZED VACCINES

NºPublicación:  AU2023378779A1 19/06/2025
Solicitante: 
SEQIRUS INC
SEQIRUS INC
AU_2023378779_A1

Resumen de: AU2023378779A1

The present disclosure relates to a fusion protein comprising an ectodomain of a viral fusion protein linked to one or more heptad repeat(s) (HR(s)) from a SARS-COV-2 spike (S) protein or a respiratory syncytial virus (RSV) F protein, and the uses thereof. The viral fusion proteins are suitable for use as vaccines.

ORAL VACCINE FOR COVID-19

NºPublicación:  WO2025125852A1 19/06/2025
Solicitante: 
ABDALI NARGESS [IR]
ABDALI, Nargess

Resumen de: WO2025125852A1

An oral vaccine for COVID-19 is disclosed. The oral vaccine for COVID-19 includes a delivery platform including Arthrospira platensis with a plurality of host genomes and a plurality of COVID-19 antigen delivery vectors coupled to the plurality of host genomes. Each respective host genome of the plurality of host genomes includes a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 1. Each COVID-19 antigen delivery vector of the plurality of COVID- 19 antigen delivery vectors has a nucleotide sequence identical to nucleotide sequence of SEQ ID NO. 2. Each respective COVID-19 antigen delivery vector of the plurality of COVID-19 antigen delivery vectors includes at least one antigen of COVID-19 with a weight ratio of the delivery platform to the at least one antigen of COVID-19in a range of 1: 10-3 to 1: 2.5 × 10-3 (delivery platform: at least one antigen of COVID-19).

METHODS OF PROMOTING LUNG HEALING AND LUNG TISSUE REGENERATION FOLLOWING INJURY OR VIRAL INFECTION

NºPublicación:  WO2025128200A1 19/06/2025
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Resumen de: WO2025128200A1

Disclosed is a method of treating lung injury in a patient comprising providing a therapeutically effective amount of a pharmaceutical agent that enhances peroxisome biogenesis to a patient. The method includes increasing the number of peroxisomes in alveolar macrophages, decreasing peroxisome degradation, and improving peroxisome function in alveolar macrophages. Increasing the number and function of peroxisomes in alveolar macrophages promotes healing of lung injury and regeneration of alveolar epithelial. The lung injury may be due to infection, including viral infection, such as SARS-CoV-2 infection or influenza infection. The lung injury may also be due to exposure to caustic substances, tobacco smoke, asbestos, or fine particulate matter.

ENGINEERED HUMAN ANTIBODIES HAVING NEUTRALIZING ACTIVITY AGAINST HUMAN CORONAVIRUS

NºPublicación:  WO2025127420A1 19/06/2025
Solicitante: 
KOREA UNIV RESEARCH AND BUSINESS FOUNDATION [KR]
\uACE0\uB824\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: WO2025127420A1

The present invention relates to engineered human antibodies having neutralizing activity against human coronavirus and use thereof. The novel human antibodies against coronavirus, of the present invention, specifically bind to SARS-CoV-1, SARS-CoV-2, or a variant thereof, exhibit neutralizing activity against SARS-CoV-1, SARS-CoV-2, or a variant thereof, and have cross-reactivity, and thus can be used for the prevention or treatment of coronavirus infection. In addition, the antibodies and fragments having immunological activities thereof can be used to rapidly detect various types of coronaviruses, and thus can be used for the immunodiagnosis of human coronaviruses, particularly SARS-CoV-2 with high infectivity, and variants thereof.

SURFACE-MODIFIED IRON OXIDE NANOPARTICLES AND VACCINE AGAINST SARS-COV-2 CONTAINING SAID SURFACE-MODIFIED IRON OXIDE NANOPARTICLES

NºPublicación:  WO2025127075A1 19/06/2025
Solicitante: 
TOHOKU UNIV [JP]
\u56FD\u7ACB\u5927\u5B66\u6CD5\u4EBA\u6771\u5317\u5927\u5B66

Resumen de: WO2025127075A1

The problem addressed is to provide surface-modified iron oxide nanoparticles for use in a vaccine exhibiting an infection preventive effect on SARS-CoV-2. The problem can be solved by surface-modified iron oxide nanoparticles comprising SARS-CoV-2 spike protein and iron oxide nanoparticles, where the spike protein of SARS-CoV-2 is bound to the surface of the iron oxide nanoparticles.

SOLUBLE GP130FC (SGP130FC) FOR USE IN THE TREATMENT OF SARS-COV-2

NºPublicación:  EP4570816A1 18/06/2025
Solicitante: 
CONSEJO SUPERIOR INVESTIGACION [ES]
Consejo Superior De Investigaciones Cient\u00EDficas - CSIC
EP_4570816_A1

Resumen de: EP4570816A1

The present invention relates to a specific inhibitor of IL-6 trans-signaling, the protein sgp130Fc, for use in the treatment or prevention of a disease caused by coronavirus infection in a subject, preferably caused by SARS-CoV-2.

2019 Loop Mediated Isothermal Amplification LAMP primer sets for detecting COVID-19 and use threreof

NºPublicación:  KR20250086567A 13/06/2025
Solicitante: 
재단법인대구경북첨단의료산업진흥재단경북대학교병원
KR_20250086567_PA

Resumen de: KR20230064339A

The present invention relates to a primer set for ring-mediated isothermal amplification to detect the 2019 novel coronavirus, a composition for detecting the 2019 novel coronavirus containing the same, a kit for detecting the 2019 novel coronavirus containing the same, and a method for detecting the 2019 novel coronavirus using the same. The primer set for ring-mediated isothermal amplification for detecting the 2019 novel coronavirus according to the present invention detects the coronavirus specifically and with high sensitivity (10-3), and can be usefully used for the detection of the coronavirus economically and easily.

ANTIVIRAL ANTISENSE OLIGOMER

NºPublicación:  US2025188469A1 12/06/2025
Solicitante: 
NIPPON SHINYAKU CO LTD [JP]
NATIONAL UNIV CORPORATION GUNMA UNIV [JP]
NIPPON SHINYAKU CO., LTD,
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY
US_2025188469_A1

Resumen de: US2025188469A1

The present specification provides an antisense oligomer, or a pharmaceutically acceptable salt thereof, or a hydrate of the antisense oligomer or the salt having a length of 15 to 30 bases, comprising a base sequence complementary to a base sequence in a target region, wherein the target region comprises a sequence of at least 10 consecutive bases in at least one region selected from the group consisting of a 5′ UTR region, a nsp1 region, a nsp10 region, an RNA-dependent RNA polymerase region, an ORF10 region, and a 3′ UTR region in the genome RNA of SARS-CoV-2, or a complementary sequence thereof, wherein the antisense oligomer, or the pharmaceutically acceptable salt thereof, or the hydrate of the antisense oligomer or the salt has an antiviral effect on a virus selected from the group consisting of SARS-CoV-2, SARS-CoV-1, and MERS-CoV.

ENRICHMENT AND CHARACTERIZATION OF RARE CIRCULATING CELLS, INCLUDING PROGENITOR CELLS, FROM PERIPHERAL BLOOD, AND USES THEREOF

NºPublicación:  US2025188542A1 12/06/2025
Solicitante: 
CORNELL UNIV [US]
HOSPITAL FOR SPECIAL SURGERY [US]
Cornell University,
Hospital for Special Surgery
US_2025188542_A1

Resumen de: US2025188542A1

The present disclosure encompasses systems, methods, and compositions for enriching a population of rare circulating cells, including progenitor cells, from peripheral blood. Specific embodiments encompass methods of analyzing rare circulating cell transcriptomic, genetic, protein expression, metabolic, epigenomic, and/or other functional assay data to identify differential gene or protein expression and/or chromatin accessibility, and/or functional characteristics. Particular methods relate to enriching and analyzing rare circulating cells in patients following COVID-19 infection, and treating the patient based on the analysis. Embodiments also relate to an enriched population of rare circulating cells from peripheral blood and uses thereof.

WATER-SOLUBLE CANNABIDIOL COMPOSITIONS AND METHOD FOR PREPARATION OF WATER-SOLUBLE CANNABIDIOL

NºPublicación:  AU2023400919A1 12/06/2025
Solicitante: 
SRICHANA TEERAPOL
SRICHANA, Teerapol
AU_2023400919_PA

Resumen de: AU2023400919A1

The present invention relates generally to a method of formulation of cannabidiol (CBD) a potential anti-inflammatory drug derived from lemon peel (d-limonene). More, particularly, the present invention relates to the enhancement of lipid soluble CBD into water soluble form in order to improve the formulation of the active component while apply in human for medication. The present invention further provides the therapeutic application of the new formulation which either neutralize and/or decreases the capability of the production of cytokines by activated immune cells during inflammatory process and hence alleviate the sufferings of illness like COVID-19 caused by SARSCoV2.

MICRORNAS FROM FORSYTHIAE FRUCTUS-ASTRAGALI RADIX COMPOUND TRADITIONAL CHINESE MEDICINE DECOCTION AS WELL AS PREPARATION METHOD AND USE THEREOF

NºPublicación:  US2025188468A1 12/06/2025
Solicitante: 
NANTONG UNIV
NANTONG UNIVERSITY
US_2025188468_A1

Resumen de: US2025188468A1

Provided are a Forsythia suspensa and Radix astragali compound traditional Chinese medicine decoction-derived micro ribonucleic acid and a preparation method therefor. The micro ribonucleic acid is selected from miRNAs with nucleotide sequences as shown in SEQ ID NOs. 1-15. Further provided are a miRNA QQ_159 with the nucleotide sequence as shown in SEQ ID NO. 14, comprising an artificially synthesized QQ_159, a plant QQ_159, a precursor form of the QQ_159, or a mature form of the QQ_159, use of the miRNA QQ_159 in the preparation of a drug for treating viral pneumonia caused by viral influenza and SARS-COV-2 virus, and a pharmaceutical composition comprising the miRNA QQ_159 and a pharmaceutically acceptable carrier.

VACCINE CONSTRUCT AND USES THEREOF

NºPublicación:  US2025186575A1 12/06/2025
Solicitante: 
THE UNIV OF MELBOURNE [AU]
The University of Melbourne
US_2025186575_A1

Resumen de: US2025186575A1

Disclosed herein are nucleic acid constructs for producing a virus-like particle (VLP) capable of raising an immune response against severe acute respiratory syndrome coronavirus (SARS-CoV), and uses thereof, wherein the constructs comprise nucleic acid sequences encoding an immunogen and a polyprotein, wherein the polyprotein comprises two or more viral structural proteins, wherein at least two of the two or more viral structural proteins are separated by a signal peptidase sequence such that, when the polyprotein is expressed in a host cell, the signal peptidase sequence undergoes host cell peptidase-dependent cleavage to liberate the two or more viral structural proteins, thereby allowing the liberated structural proteins to self-assemble into a VLP carrying the immunogen.

SARS-COV-2 SUBUNIT VACCINE

NºPublicación:  US2025186576A1 12/06/2025
Solicitante: 
HIPRA SCIENT S L U [ES]
LABORATORIOS HIPRA S A [ES]
HIPRA SCIENTIFIC, S.L.U,
LABORATORIOS HIPRA, S.A
US_2025186576_A1

Resumen de: US2025186576A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

RECOMBINANT NEWCASTLE DISEASE VIRUSES AND IMMUNOGENIC COMPOSITIONS FOR USE IN PREVENTING COVID-19

NºPublicación:  US2025186578A1 12/06/2025
Solicitante: 
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI [US]
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
US_2025186578_A1

Resumen de: US2025186578A1

Described herein are recombinant Newcastle disease viruses (“NDVs”) comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NDV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of COVID-19.

ALLOSTERIC INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2

NºPublicación:  US2025186374A1 12/06/2025
Solicitante: 
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA [US]
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA,
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
US_2025186374_A1

Resumen de: US2025186374A1

SARS-CoV-2 has raised the alarm to search for effective therapy for this virus. To date several vaccines have been approved, but few available drugs reported recently still need approval from FDA. Antiviral compositions having niclosamide derivatives were prepared for treating COVID-19. Using a FRET-based enzymatic assay, three niclosamide derivatives, JMX0286, JMX0301, and JMX0941, were identified as potent allosteric inhibitors against SARS-CoV-2 3CLpro, with IC50 values similar to that of known covalent inhibitor boceprevir. In a cell-based antiviral assay, these inhibitors can inhibit the virus growth with EC50 in the range of 2-3 μM. The mechanism of action of JMX0286, JMX0301, and JMX0941 were characterized by enzyme kinetics, affinity binding and protein-based substrate digestion. Molecular docking suggested that JMX0286, JMX0301, and JMX0941 bind specifically to an allosteric pocket of the SARS-CoV-2 3CL protease.

SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 PEPTIDES ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THEREOF NUCLEIC ACIDS RECOMBINANT EXPRESSION VECTORS CELLS MATERIALS FOR DETECTING SARS-COV-2 NUCLEOPROTEIN ONE-STEP SARS-COV-2 DIAGNOSTIC KIT AND ONE-STEP SARS-COV-2 DIAGNOSTIC METHOD

NºPublicación:  KR20250085005A 12/06/2025
Solicitante: 
연세대학교산학협력단
KR_20250085005_PA

Resumen de: KR20250085005A

펩타이드, 항체 또는 이의 항원 결합 단편, 핵산, 재조합 발현 벡터, 세포, SARS-CoV-2 핵단백질 검출용 물질, 원스텝 SARS-CoV-2 진단 키트 및 원스텝 SARS-CoV-2 진단 방법이 개시된다.

TRIAZINE COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF

NºPublicación:  US2025188102A1 12/06/2025
Solicitante: 
JKT BIOPHARMA CO LTD [CN]
JKT BIOPHARMA CO., LTD
US_2025188102_A1

Resumen de: US2025188102A1

A triazine compound, an intermediate thereof, and a preparation method therefor and the use thereof. Specifically, the present invention relates to a triazine derivative as represented by formula (I′) or a pharmaceutically acceptable salt thereof. On the basis of retaining the effectiveness against SARS-CoV-2, the compound significantly prolongs the half-life period, reduces the dosage requirement, reduces side effects, expands the range of therapeutic window, and has very good prospects when used for manufacturing a drug for treating diseases related to coronavirus infections.

PEPTIDE SPECIFICALLY BINDING TO CORONAVIRUS NUCLEOPROTEIN

NºPublicación:  WO2025121804A1 12/06/2025
Solicitante: 
UIF UNIV INDUSTRY FOUNDATION YONSEI UNIV [KR]
\uC5F0\uC138\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: WO2025121804A1

Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting porcine epidemic diarrhea virus, a one-step diagnostic kit for porcine epidemic diarrhea, and a one-step diagnostic method for porcine epidemic diarrhea. Disclosed are a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, a recombinant expression vector, a cell, a substance for detecting SARS-CoV-2 nucleoprotein, a one-step SARS-CoV-2 diagnostic kit, and a one-step SARS-CoV-2 diagnostic method.

VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

NºPublicación:  WO2025122814A1 12/06/2025
Solicitante: 
PRIDGEN WILLIAM LANGLEY [US]
PRIDGEN, William Langley
US_2025186443_A1

Resumen de: WO2025122814A1

The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

SIALIC-ACID LIGAND DECORATED THERAPEUTICS

NºPublicación:  US2025186609A1 12/06/2025
Solicitante: 
AVICEDA OPHTHALMICS INC [US]
AVICEDA OPHTHALMICS, INC
US_2025186609_A1

Resumen de: US2025186609A1

The present disclosure provides methods and compositions for modulating the activity of self-associated molecular pattern recognition receptors such as for example, Siglec (sialic-acid-binding immunoglobulin-type lectins) and complement factor H (CFH). Modulating the activity of infectious organisms such as viral influenza A, B, C, SARS-CoV1, 2, and cancer/tumor cells such as lung, breast and skin cancers. The compositions comprise a particle, comprising a molecule represented by the following structural formula:P-L-G,wherein P is a biocompatible polymer scaffold comprising at least one biocompatible polymer defined herein, G is a polysialic acid (PSA) comprising from 5 to 200 repeat units of sialic acid; and L is a covalent linker, or a pharmaceutically acceptable salt thereof.

BIOLOGICALLY PRODUCED NUCLEIC ACID FOR VACCINE PRODUCTION

NºPublicación:  US2025188127A1 12/06/2025
Solicitante: 
UNIV BASEL [CH]
Universit\u00E4t Basel
US_2025188127_A1

Resumen de: US2025188127A1

The invention relates to a biologically produced nucleic acid sequence comprising two or three primary nucleic acid sequence parts of SARS-COV-2 and not more than three secondary nucleic acid sequence parts, wherein a secondary nucleic acid sequence part encodes an amino acid sequence having the function of a SARS-COV-2 amino acid sequence encoded by ORF3a, ORF6, ORF7a or ORF8. The invention further relates to a host cell or a kit for producing the nucleic acid of the invention, a vector encoding the nucleic acid of the invention and products that can be obtained by the expression of the nucleic acid of the invention such as virus envelopes. The invention further relates a pharmaceutical composition comprising the nucleic acid of the invention or products derived thereof, preferably for use in the prevention of SARS-COV-2.

GLYCOFORM SPECIFIC NANOBODIES AND METHODS OF USE

NºPublicación:  US2025188193A1 12/06/2025
Solicitante: 
THE ROCKEFELLER UNIV [US]
The Rockefeller University
US_2025188193_A1

Resumen de: US2025188193A1

This disclosure is based, at least in part, on an unexpected discovery that the novel nanobodies and variants thereof are able to specifically bind afucosylated or sialylated IgG Fc glycoforms. Glycosylation of the IgG Fc domain is a major determinant of the strength and specificity of antibody effector functions, modulating the binding interactions of the Fc with the diverse family of Fey receptors. These Fc glycan modifications, such as removal of the core fucose residue, are newfound clinical markers for predicting severity of diseases, such as diseases caused by dengue virus (DENV) or SARS-CoV-2. However, it remains challenging to accurately distinguish specific IgG glycoforms without costly and time-intensive methods. The novel glycol-specific nanobodies and variants thereof, as disclosed herein, can be used as rapid clinical diagnostics or prognostics to risk stratify patients with viral and inflammatory diseases, as well as therapeutics for patient treatment.

PREPARATION METHOD AND APPLICATION OF SINGLE-CHAIN ANTIBODY FRAGMENT TARGETING SARS-COV-2 NUCLEOCAPSID PROTEIN

NºPublicación:  US2025188155A1 12/06/2025
Solicitante: 
NANJING UNIV [CN]
NANJING UNIVERSITY
US_2025188155_A1

Resumen de: US2025188155A1

Disclosed are a preparation method and application of a single-chain antibody fragment targeting SARS-COV-2 nucleocapsid protein, aiming to provide a single-chain antibody fragment with high affinity and strong specificity. The present disclosure obtains three single-chain antibody fragments targeting SARS-COV-2 nucleocapsid protein through construction of a nanobody phage library and phage screening technology. The single-chain antibody fragment consists of a heavy chain variable region, a 15aa connecting peptide, and a light chain variable region connected in sequence, and has an amino acid sequence shown in SEQ ID NO: 1-SEQ ID NO: 3. The single-chain antibody fragment in the present disclosure has excellent binding performance and specificity with the SARS-COV-2 nucleocapsid protein, can be applied to a variety of immunoassay platforms of the SARS-COV-2, and has broad application prospects in the field of SARS-COV-2 detection.

VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

NºPublicación:  US2025186443A1 12/06/2025
Solicitante: 
PRIDGEN WILLIAM LANGLEY [US]
PRIDGEN William Langley
US_2025186443_A1

Resumen de: US2025186443A1

The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19

NºPublicación:  ES3026632T3 11/06/2025
Solicitante: 
SZEKERES THOMAS
JAEGER WALTER
Szekeres, Thomas,
J\u00E4ger, Walter
US_2024166587_PA

Resumen de: US2024166587A1

The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.

METHOD FOR MANUFACTURING INACTIVATED SARS-COV-2 VACCINE, INACTIVATED SARS-COV-2 VACCINE, METHOD FOR PURIFYING SARS-COV-2 OR INACTIVATED SARS-COV-2, AND SARS-COV-2 ANTIGEN COMPOSITION OR INACTIVATED SARS-COV-2 ANTIGEN COMPOSITION

NºPublicación:  EP4566625A1 11/06/2025
Solicitante: 
KM BIOLOGICS CO LTD [JP]
KM Biologics Co., Ltd
EP_4566625_PA

Resumen de: EP4566625A1

The present invention relates to a production method of an inactivated SARS-CoV-2 vaccine, the method including: a step of bringing a SARS-CoV-2 containing solution or an inactivated SARS-CoV-2 containing solution into contact with a cellulose sulfate ester gel at a pH of 8 or more and 10 or less to adsorb the SARS-CoV-2 or the inactivated SARS-CoV-2 to the gel; then removing impurities; and then eluting and recovering the SARS-CoV-2 or the inactivated SARS-CoV-2.

SARS-COV2 MAIN PROTEASE INHIBITORS

NºPublicación:  EP4565574A1 11/06/2025
Solicitante: 
GILEAD SCIENCES INC [US]
GILEAD SCIENCES, INC
CR_20250040_A

Resumen de: CN119731159A

The present disclosure relates to compounds of formula (I): # imgabs0 # and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of viral infections, such as coronavirus infections.

mRNA vaccine encoding fusion antigen against Mpox and severe acute respiratory syndrome coronavirus 2

NºPublicación:  US12324835B1 10/06/2025
Solicitante: 
ACAD OF MILITARY MEDICAL SCIENCES AMS PLA [CN]
ACADEMY OF MILITARY MEDICAL SCIENCES, AMS, PLA
US_12324835_B1

Resumen de: US12324835B1

An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.

SARS-CoV-2 SARS-CoV-2 spike phylogenetically optimized mosaic antigen having cross immunogenicity and vaccine comprising the same

NºPublicación:  KR20250083067A 09/06/2025
Solicitante: 
고려대학교산학협력단대한민국질병관리청국립보건연구원장

Resumen de: KR20250083067A

본 발명은 계통수 분석 기반 교차 면역원성을 갖는 SARS-CoV-2 스파이크 모자이크 항원 및 이를 포함하는 백신에 관한 것으로서, 본 발명의 SARS-CoV-2 바이러스 모자이크 항원은 SARS-CoV-2 바이러스 변이주의 스파이크 단백질 서열을 모자이크 기법을 통해 조합하고 추가적인 아미노산 잔기를 치환하여, 초기 prototype, 알파 변이주, 베타 변이주, 감마 변이주, 델타 변이주 및 오미크론 변이주 등과 같은 다양한 SARS-CoV-2 변이주에 대한 범용성을 가지는 백신의 용도로서 유용하게 사용될 수 있다.

PEGYLATED SERP-1 PROTEIN TREATMENT IMPROVES OUTCOMES AFTER SARS-COV-2 INFECTION

NºPublicación:  US2025177541A1 05/06/2025
Solicitante: 
ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIV [US]
SERPASS BIOLOGICS INC [US]
Arizona Board of Regents on behalf of Arizona State University,
Serpass Biologics, Inc
US_2025177541_PA

Resumen de: US2025177541A1

Disclosed herein are methods of treating a lung disorder. In some embodiments, the lung disorder includes an acute respiratory syndrome. In some embodiments, the treatment includes administering to a subject in need thereof, a modified Serp-1 protein. The modified Serp-1 protein may include a therapeutic enhancing moiety. In some embodiments, the therapeutic enhancing moiety is a water soluble polymer such as polyethylene glycol.

MEASUREMENT OF NUCLEIC ACIDS IN A BIOLOGICAL SPECIMEN USING RT-LAMP

NºPublicación:  US2025179581A1 05/06/2025
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California
US_2025179581_PA

Resumen de: US2025179581A1

Methods and devices for utilizing reverse transcription loop-mediated isothermal amplification (RT-LAMP) to detect target DNA and RNA sequences for diagnostic and experimental assays, such as those for diagnosing and quantifying diseases, such as colorectal cancer and gastrointestinal disease, or pathogens, such as SARS-COV-2.

SANGUISORBA OFFICINALIS LINNE EXTRACT COMPOSITION INHIBITING 3CL PROTEASE AND RDRP ACTIVITY OF SARS-COV-2

NºPublicación:  US2025177469A1 05/06/2025
Solicitante: 
QGENETICS CO LTD [KR]
QGENETICS CO., LTD
US_2025177469_PA

Resumen de: US2025177469A1

The present invention relates to a use of a novel Sanguisorba officinalis Linne extract to inhibit SARS-CoV-2 virus 3CL protease and RdRp activity. The composition including the Sanguisorba officinalis Linne extract of the present invention as an active ingredient inhibits 3CL protease and RdRp activity and thus is effective in preventing or treating infection by SARS-CoV-2 and a variant virus thereof.

SARS-COV-2 NEUTRALIZING SYNTHETIC PROTEINS

NºPublicación:  US2025179152A1 05/06/2025
Solicitante: 
THE TEXAS A&M UNIV SYSTEM [US]
THE TEXAS A&M UNIVERSITY SYSTEM
US_2025179152_A1

Resumen de: US2025179152A1

The present disclosure relates to compositions and methods for the treatment and/or prevention of SARS-COV-2 infections. In one embodiment the method comprises the delivery of a pharmaceutical composition comprising a SARS-COV-2 neutralizing synthetic protein, optionally wherein the protein is a trimeric protein composed of designed ankyrin repeat protein (DARPin) fused with a T4 foldon peptide that is administered non-invasively such as by nasal inhalation.

SPIKE FURIN CLEAVAGE IS A SARS-COV-2 TARGETING STRATEGY TO BREAK THE CHAIN OF INFECTION CYCLE

NºPublicación:  US2025179151A1 05/06/2025
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION [US]
University of Virginia Patent Foundation
US_2025179151_PA

Resumen de: US2025179151A1

Provided are methods for treating viral infections in subject in need thereof. In some embodiments, the method include administering to the subject a composition that has an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike. Also provided are compositions that include an effective amount of an agent that selectively interferes with host protease function to inhibit fusion-ready viral fragment generation, optionally S2 in case of SARS-CoV2 or GP160 or GP120 in case of HIV, and/or to destabilize a full-length viral fusion protein, optionally SARS-CoV-2 spike, which compositions can optionally be employed in the disclosed methods.

SCO-spondin-derived polypeptides for enhancing synaptic transmission

NºPublicación:  US2025177481A1 05/06/2025
Solicitante: 
AXOLTIS PHARMA [FR]
AXOLTIS PHARMA
US_2025177481_PA

Resumen de: US2025177481A1

The invention relates to polypeptides derived from SCO-spondin for increasing or enhancing the basal excitatory synaptic transmission, notably glutamatergic neurotransmission. More particularly the invention relates to said polypeptides for increasing or enhancing glutamatergic neurotransmission in diseases or conditions comprising psychiatric disorders; drug addiction; viral infection (such as coronaviruses, e.g. SARS CoV2) related neurological symptoms; NMDA receptor (NMDAr) and/or AMPA receptor (AMPAr) deficiency related disease, notably anti-NMDAr encephalitis; vegetative state, and hypoxic brain injury. The present invention also relates to methods of treatment.

ANTIVIRAL AGENTS FOR TREATMENT OF CORONAVIRUSES

NºPublicación:  US2025177434A1 05/06/2025
Solicitante: 
MEHARRY MEDICAL COLLEGE [US]
Meharry Medical College
US_2025177434_PA

Resumen de: US2025177434A1

An antiviral agent is provided, having a phosphorodiamidate morpholino oligomer with an antisense sequence to a portion of a genome of a strain of a coronavirus. The coronavirus may be SARS-CoV-2 or another βCoV. The antiviral agent finds many uses, such as in a pharmaceutical composition, a method of treating coronavirus-mediated disease, a method of preventing coronavirus-mediated disease, a method of reducing or preventing the replication of coronavirus in a host cell, a method of controlling the spread of coronavirus in donated tissue, a treated tissue sample, and in the manufacture of a medicament for the treatment or prevention or coronavirus-mediated disease.

Method for Rapid Capture, Detection and Analysis of Viruses on Surfaces

NºPublicación:  US2025180560A1 05/06/2025
Solicitante: 
NORTHEASTERN UNIV [US]
Northeastern University
WO_2023173046_PA

Resumen de: US2025180560A1

Provided herein are, in various embodiments, methods and kits for assaying one or more virions. In certain embodiments, the methods and kits of the disclosure provide for the calculation of virion titer and/or virion infectivity. In still further embodiments, the disclosure provides for methods and kits for enhancing assaying of viruses such as SARS-CoV-2.

Real-Time Contactless Bio-Threat Screening

NºPublicación:  US2025180506A1 05/06/2025
Solicitante: 
POSTREL RICHARD [US]
Postrel Richard
WO_2023133331_A2

Resumen de: US2025180506A1

This present invention provides a system, method, and device for rapidly screening individuals at a high rate of speed. The invention features a method, system and device that analyzes an individual's body odors to determine the presence or absence of a disease such as COVID-19 and/or its variants. The invention allows for real-time testing for a pathogen, a disease, or other condition of interest that is especially useful when testing every individual entering or exiting a venue or transitioning through any controlled entry or exit zone demarcated by a portal, passage, security zone, or gate, etc. This testing requires no invasive sampling—or even touch contact—between the device or device operator and the person being tested. The device features a sensing surface whose electronic activity is a function volatile organic compounds (body odor) in the immediate vicinity of its surface.

Vaccine compositions for mucosal immune response

NºPublicación:  AU2025203389A1 05/06/2025
Solicitante: 
NANT HOLDINGS IP LLC
NANTCELL INC
Nant Holdings IP, LLC,
Nantcell Inc
AU_2025203389_A1

Resumen de: AU2025203389A1

Abstract A vaccine composition comprising a lyophilized, adenovirus-based expression vector encoding a disease antigen, and a stabilizing compound, such as aragonite. The disease antigen may comprise a viral protein or fragment thereof, such as a SARS-CoV2 virus protein. Further provided are compositions that include a solid dosage form made from aragonite for loading and delivery of a vaccine composition.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

NºPublicación:  US2025177428A1 05/06/2025
Solicitante: 
THE REGENTS OF THE UNIV OF CALIFORNIA [US]
The Regents of the University of California
US_2025177428_A1

Resumen de: US2025177428A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

COVID-19 Monitoring method for treatment of COVID-19 virus variants

NºPublicación:  KR20250077973A 02/06/2025
Solicitante: 
한국기초과학지원연구원대한민국질병관리청국립보건연구원장

Resumen de: KR20250077973A

본 발명은 개체의 아르기닌(Arginine) 대사경로 활성화를 확인하는 단계;를 포함하는, COVID-19 코로나바이러스 변이주 감염의 모니터링 방법에 관한 것으로, 본 발명의 모니터링 방법은 COVID-19 코로나바이러스 변이주 감염 개체에서 아르기닌 대사에 관여하는 전사체 및 대사체의 변화를 확인함으로써, 효과적으로 COVID-19 코로나바이러스 변이주 감염을 진단할 수 있다.

COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19

NºPublicación:  PL4313010T3 02/06/2025
Solicitante: 
SZEKERES THOMAS [AT]
JAEGER WALTER [AT]
Szekeres, Thomas,
J\u00E4ger, Walter
US_2024166587_PA

Resumen de: US2024166587A1

The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.

Crystal forms of an anti-sars cov-2 agent

NºPublicación:  IL320050A 01/06/2025
Solicitante: 
ENANTA PHARMACEUTICALS INC [US]
ZHU KAICHENG
WANG TAO
HELBLE JOSEPH
TOTO ANTHONY
ZHANG JIAJUN
WU GEORGE G
OR YAT SUN
ENANTA PHARMACEUTICALS INC,
ZHU Kaicheng,
WANG Tao,
HELBLE Joseph,
TOTO Anthony,
ZHANG Jiajun,
WU George G,
OR Yat Sun
IL_320050_A

Resumen de: AU2023356620A1

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

Treatment using a one-to-stop attenuated sars-cov-2 virus

NºPublicación:  IL320118A 01/06/2025
Solicitante: 
UNIVERSIT?T BERN [CH]
INST F?R VIROLOGIE UND IMMUNOLOGIE IVI [CH]
ROCKETVAX AG [CH]
THIEL VOLKER [CH]
EBERT NADINE [CH]
TRUEB BETTINA SALOME [CH]
BARUT G?LIZ TUBA [CH]
KRATZEL ANNIKA [CH]
JORES J?RG [CH]
LABROUSSAA FABIEN [FR]
BEER MARTIN [DE]
HOFFMANN DONATA [DE]
SCH?N JACOB [DE]
HALWE NICO JOEL [DE]
ULRICH LORENZ [DE]
UNIVERSIT?T BERN,
INSTITUT F?R VIROLOGIE UND IMMUNOLOGIE (IVI),
ROCKETVAX AG,
THIEL Volker,
EBERT Nadine,
TRUEB Bettina Salome,
BARUT G?liz Tuba,
KRATZEL Annika,
JORES J?rg,
LABROUSSAA Fabien,
BEER Martin,
HOFFMANN Donata,
SCH?N Jacob,
HALWE Nico Joel,
ULRICH Lorenz
IL_320118_A

Resumen de: AU2023361023A1

The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

Method for improving immunogenicity of protein/peptide antigen

NºPublicación:  NZ795032A 30/05/2025
Solicitante: 
SINOCELLTECH LTD
SinoCellTech Ltd
MX_2022013456_A

Resumen de: NZ795032A

Disclosed is a method for improving the immunogenicity of a protein/peptide antigen, the method comprising conjugating a protein/peptide antigen with a sugar to form a sugar-protein/peptide antigen conjugate, which has improved immunogenicity compared to an unconjugated protein/peptide antigen. In particular, the method involves conjugating a pathogen, such as a viral surface protein antigen or a fragment thereof selected from human respiratory syncytial virus glycoprotein G (RSV-gpG), hepatitis C virus envelope glycoprotein E1 protein (HCV-E1), hepatitis C virus envelope E2 protein (HCV-E2), influenza B hemagglutinin protein (Flu-B-HA1), influenza A H5N1 hemagglutinin (H5N1-HA), ebola virus glycoprotein (Ebola-GP), ebola virus hlycoprotein GP1 (Ebola-GP1), zika virus envelope protein (ZIKV-E), and/or coronavirus spike protein, with a polysaccharide, in particular a capsular polysaccharide of Streptococcus pneumonia. The conjugate with improved immunogenicity can be used to prevent or treat diseases caused by pathogens, in particular diseases caused by coronaviruses.

OPTIMIZED SARBECOVIRUS SPIKE S2 SUBUNIT BINDERS AND COMPOSITIONS COMPRISING THE SAME

NºPublicación:  WO2025109176A1 30/05/2025
Solicitante: 
EXEVIR BIO BV [BE]
VIB VZW [BE]
UNIV GENT [BE]
EXEVIR BIO BV,
VIB VZW,
UNIVERSITEIT GENT

Resumen de: WO2025109176A1

This invention relates to Sarbecovirus binding agents, in particular antibodies and antigen-binding fragments thereof, which are capable of potently neutralizing a Sarbecovirus, in particular capable of neutralizing any one or both of SARS-CoV-2, including SARS-CoV-2 variants, and SARS-CoV- 1, and affinity matured variants thereof. The binding agents, in particular the antibodies and antibody fragments, have one or more favourable antibody development characteristics. The invention also relates to methods using these binding agents and uses thereof.

VZV ANTIGEN VARIANT, NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND USE THEREOF

NºPublicación:  WO2025108306A1 30/05/2025
Solicitante: 
SHANGHAI RNACURE BIOPHARMA CO LTD [CN]
\u4E0A\u6D77\u84DD\u9E4A\u751F\u7269\u533B\u836F\u6709\u9650\u516C\u53F8
CN_120020142_A

Resumen de: WO2025108306A1

Disclosed are a VZV antigen variant, a nucleic acid, a pharmaceutical composition and the use thereof. The VZV antigen variant has a difference of Y582G compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has deletions at positions 561-623, 569-623 or 574-623 compared to an amino acid sequence as set forth in SEQ ID NO: 1; and/or the VZV antigen variant has a modification of a transmembrane region and intracellular region of a protein compared to an amino acid sequence as set forth in SEQ ID NO: 1, wherein the modification of the transmembrane region and intracellular region of the protein involves the replacement of a transmembrane region and intracellular region of an original VZV antigen with a transmembrane region of a SARS-CoV-2Spike protein or a transmembrane region of an influenza H protein. The VZV antigen variant has a stronger immunogenicity than the VZV antigen in the prior art, can achieve a higher titer of binding antibodies, and has a higher protection efficacy.

SMALL PEPTIDES FOR INHIBITING SARS-COV-2 SPIKE PROTEIN-AND LPS-INDUCED INFLAMMATION AND CYTOKINE PRODUCTION

NºPublicación:  WO2025111412A1 30/05/2025
Solicitante: 
THE CURATORS OF THE UNIV OF MISSOURI [US]
THE CURATORS OF THE UNIVERSITY OF MISSOURI

Resumen de: WO2025111412A1

Small anti-inflammatory peptide for blocking NF-κB are disclosed herein. The peptides as well as compositions including the peptides can be administered to inhibit cytokine production and/or inhibit pulmonary inflammation in a subject in need. Particularly embodiments include administration to a subject suffering from coronavirus disease 2019 (COVID-19).

FORMULATION OF AN INHALABLE QUERCETIN SOLUTION FOR THE MANAGEMENT OF RESPIRATORY DISEASES

NºPublicación:  WO2025108530A1 30/05/2025
Solicitante: 
SARL LABORATOIRE BEKER [DZ]
SARL LABORATOIRE BEKER

Resumen de: WO2025108530A1

The present invention describes the formulation of a phytotherapy product, namely an inhalable solution developed from a natural extract of quercetin, either alone or in combination with resveratrol, rigorously selected for their synergistic effects on the respiratory system and their potential in alleviating symptoms associated with respiratory diseases such as asthma, COPD, lung cancer, COVID-19, and long COVID. The solution is intended to be inhaled using a nebuliser or other inhalation device intended to transform the solution into an aerosol in order to have a direct effect on the bronchi and minimise side effects. Quercetin has anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties. This document describes, through various examples, the manufacturing process developed to obtain a solution for inhalation.

TRYPTANTHRIN DERIVATIVES WITH THIOSEMICARBAZONE SUBSTITUTION AND USE THEREOF

NºPublicación:  US2025171449A1 29/05/2025
Solicitante: 
UNIVERZITA KARLOVA [CZ]
UNIVERZITA KARLOVA
US_2025171449_PA

Resumen de: US2025171449A1

The invention relates to tryptanthrin derivatives with thiosemicarbazone substitution of the general formulae I and II, where R1-R8 are independently H, OH, alkyl with 1 to 6 carbon atoms, C(CH3)3, allyl, propargyl, ben-zyl, phenyl, F, Cl, Br, I, CH2OH, O (alkyl), CF3, OCF3, CN, COOH, COO(alkyl), CONH2, CONH(alkyl), NO2, N(alkyl)2, NH(alkyl), NHCO(alkyl), where the alkyl has 1 to 6 carbon atoms, or R1-R2 or R2-R3 or R3-R4 or R5-R6 or R6-R7 or R7-R8 is —CH═CH—CH═CH—, i.e., a fused benzene ring, X and Z are independently H, alkyl of 1 to 6 carbon atoms, benzyl or phenyl. The compounds combine a structural motif suitable for PLpro targeting, have strong affinity and selectivity for RNA over DNA, and at the same time effectively chelate ferric and ferrous ions. Thus, these compounds have the desired properties for potential use as inhibitors of the production of SARS-COV-2 viral particles and can thus be used for the preparation drugs for the treatment of coronavirus diseases, especially COVID-19.

N4-ISOBUTYRYLOXYCYTIDINE ANALOG SYNTHESIS AND COMPOSITION FOR TREATING VIRAL INFECTION COMPRISING ANTI-VIRAL USE THEREOF

NºPublicación:  US2025171486A1 29/05/2025
Solicitante: 
DONG A UNIV RESEARCH FOUNDATION FOR INDUSTRY ACADEMY COOPERATION [KR]
Dong-A University Research Foundation for Industry-Academy Cooperation
US_2025171486_A1

Resumen de: US2025171486A1

The present disclosure relates to N4-isobutyryloxycytidine analog synthesis and to the anti-viral use thereof against dengue virus, influenza virus, and SARS-COV-2 virus.

COMPOSITIONS AND METHODS FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), INFLUENZA A AND INFLUENZA B

NºPublicación:  US2025171862A1 29/05/2025
Solicitante: 
ROCHE MOLECULAR SYSTEMS INC [US]
Roche Molecular Systems, Inc
US_2025171862_PA

Resumen de: US2025171862A1

Methods for the rapid detection of the presence or absence of SARS-CoV-2, influenza A and influenza B in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers and probes targeting SARS-CoV-2, influenza A, and influenza B and kits are provided that are designed for the detection of SARS-CoV-2, influenza A and influenza B.

CDP-CHOLINE A HOST-DIRECTED THERAPEUTIC FOR DISEASE CAUSED BY SARS COV-2 INFECTION

NºPublicación:  US2025170246A1 29/05/2025
Solicitante: 
OHIO STATE INNOVATION FOUND [US]
Ohio State Innovation Foundation
US_2025170246_PA

Resumen de: US2025170246A1

Compositions and methods are disclosed for treating coronavirus infections, such as SARS CoV-2 coronavirus infections. For example, a composition is disclosed that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDP-ethanolamine (CDP-ETH), and CDPdiacylglycerol (CDP-DAG) in combination with one or more agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals, in a pharmaceutically acceptable carrier. Also disclosed is a method of treating coronavirus (e.g. SARS CoV-2) infection in a subject that involves administering to the subject one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDPethanolamine (CDP-ETH), and CDP-diacylglycerol (CDP-DAG) in combination with agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals.

ACTION OF L-CITRULLINE TO PREVENT OR TREAT ENDOTHELIAL DYSFUNCTION

NºPublicación:  US2025170084A1 29/05/2025
Solicitante: 
ASKLEPION PHARMACEUTICALS LLC [US]
VANDERBILT UNIV [US]
Asklepion Pharmaceuticals, LLC,
Vanderbilt University
US_2025170084_PA

Resumen de: US2025170084A1

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.

RAPID METHOD FOR ROOM TEMPERATURE REVERSE TRANSCRIPTION LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (RT-LAMP) AND REAGENT KIT

NºPublicación:  US2025171864A1 29/05/2025
Solicitante: 
D NOME PRIVATE LTD [IN]
D NOME [IN]
D-NOME PRIVATE LIMITED,
D-NOME
US_2025171864_PA

Resumen de: US2025171864A1

The present invention relates to a rapid method to perform reverse transcription loop-mediated isothermal amplification (RT-LAMP) and LAMP at room temperature between 25-42° C., more specifically at 25-37° C., to detect RNA/DNA in a sample and a reagent kit thereof. Further, the invention relates to an in vitro method to detect SARS-CoV2 using RT-LAMP at room temperature between 25-42° C., more specifically at 37° C. The reagent kit comprises of enzymes/proteins—Klenow exo−/−, ApaI, High fidelity Taq Pol, Rpa32, StpA, AMV-RT for reverse transcriptase; buffer composition of—Tris-HCl, MgSO4, KCl, DTT, PEG, DMSO, 1 mM dNTPs each, at least 4 primers, and fluorescent or colorimetric dye.

DEVICE TO CLOSE TOILET LID BEFORE FLUSHING

NºPublicación:  US2025169661A1 29/05/2025
Solicitante: 
WILEWSKI ADAM PHILIP [SE]
PENZO JESSICA MARIA [SE]
Wilewski Adam Philip,
Penzo Jessica Maria
US_2025169661_PA

Resumen de: US2025169661A1

Device to close a toilet lid before flushing contains a base part (2) in which a drive device in form of an electrical motor (7) is situated. On top of the base part (2) a motion detector (5) is located that controls a movable arm (3). Within the base part a motherboard (6) is situated. With help from the movement that emerge when flushing the motion detector (5) is activated, that in turn activates the electrical motor (7) that is connected with the movable arm (3) on the front side of the base part (2). The arm (3) opens up 45 degrees, pushes the toilet lid and returns to the origin mode. The detector (4) senses that the lid is no longer resting against the base part (2) and shuts of the device (1). In this way the source of the power consumption, which is a rechargeable battery (3), is limited. The lid is closed completely before flushing and bacteria, virus and the spread of Covid 19 is reduced.

DUPILUMAB FOR TREATMENT OF COVID-19

NºPublicación:  US2025171546A1 29/05/2025
Solicitante: 
UNIV OF VIRGINIA PATENT FOUNDATION [US]
UNIVERSITY OF VIRGINIA PATENT FOUNDATION
US_2025171546_PA

Resumen de: US2025171546A1

Methods for treating coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, are described. The methods include administration of combinations of agents, including combinations that include dupilumab. The methods can be used to treat subjects diagnosed with a SARS-CoV-2 infection, including those already hospitalized to treat COVID-19 and/or those also having lymphopenia, to reduce the severity of outcomes related to COVID-19, such as admittance to the intensive care unit (ICU), mechanical ventilation, and/or death, particularly over periods of time longer than a month or two months following the initial administration of the agents. Compositions for use in the treatment of COVID-19 are also described.

ANTIVIRAL PEPTIDES AND METHODS OF USE THEREOF

NºPublicación:  US2025171511A1 29/05/2025
Solicitante: 
VERSITECH LTD [CN]
CENTRE FOR VIROLOGY VACCINOLOGY AND THERAPEUTICS LTD [CN]
Versitech Limited,
Centre for Virology, Vaccinology and Therapeutics Limited
US_2025171511_PA

Resumen de: US2025171511A1

Antiviral peptides and formulations thereof are described for use in treating or preventing one or more symptoms of coronavirus infections. Peptides derived from human beta defensin 2 have been shown to have antiviral properties against different variants of coronavirus including cross-linking viral particles, blocking cell-to-cell fusion, and/or inhibiting viral release. Pharmaceutical compositions and methods of using one or more antiviral peptides are also provided. Preferably, the antiviral peptides are administered via intranasal route to prevent or alleviate one or more symptoms of coronavirus infections such as reducing the syncytial formation and lung damage.

COVID-19 AND RESPIRATORY DISEASE VIRUS INFECTION MODELS USING LUNG ORGANOIDS

NºPublicación:  EP4560010A1 28/05/2025
Solicitante: 
CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION [KR]
The Catholic University Of Korea Industry-Academic Cooperation Foundation
EP_4560010_PA

Resumen de: EP4560010A1

The present invention relates to a COVID-19 infection model using alveolar organoids. Respiratory virus-infected alveolar organoids produced according to the present invention are expected to be usefully used in preclinical or clinical drug screening and the like for the development of therapeutic agents for SARS-CoV-2 infection.

ENVELOPED VIRUS LIKE PARTICLES COMPRISING SARS-COV-2 S PROTEIN

NºPublicación:  EP4558623A1 28/05/2025
Solicitante: 
NAT RES COUNCIL CANADA [CA]
National Research Council of Canada
WO_2024018364_PA

Resumen de: WO2024018364A1

Provided is an enveloped virus-like particle (eVLP) comprising a substantially full-length recombinant SARS-CoV-2 spike (S) protein. The eVLP may further comprise an additional recombinant SARS-CoV-2 S protein having a different sequence, another recombinant viral antigen, or a recombinant non-viral protein. The eVLP is derived from an animal cell, such as a CHO cell, expressing the recombinant SARS-CoV-2 spike protein. Also provided are methods of producing such eVLPs, compositions including such eVLPs, and methods and uses for the induction of an immune response against a SARS-CoV-2 spike protein and/or prevention of COVID-19 or SARS-CoV-2 infection, employing such eVLPs.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

NºPublicación:  HUE070285T2 28/05/2025
Solicitante: 
RQBIO COVID LTD [GB]
RQBio Covid Limited
MA_61946_B1

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

METHOD FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) DETECTION ON BASIS OF RECEPTOR BINDING

NºPublicación:  ZA202407723B 28/05/2025
Solicitante: 
CENTRAL HOSPITAL OF MINHANG DISTR SHANGHAI [CN]
CENTRAL HOSPITAL OF MINHANG DISTRICT SHANGHAI
WO_2024055843_PA

Resumen de: ZA202407723B

The present disclosure provides a method for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection on the basis of receptor binding, including: subjecting crosslinked agarose as a matrix to surface carboxyl modification to obtain a magnetic agarose microsphere, and covalently coupling the magnetic agarose microsphere with a receptor protein to obtain a receptor protein-coupled magnetic agarose microsphere; allowing the receptor protein covalently binding to a surface of the receptor protein-coupled magnetic agarose microsphere to recognize and bind to a receptor-binding domain (RBD) of an outer membrane protein S of a SARS-CoV-2 sample, which simulates a binding process of the SARS-CoV-2 to a host cell to capture the SARS-CoV-2; subjecting the magnetic microsphere to washing, purification, and elution successively to obtain the SARS-CoV-2 with a cell binding ability; and detecting by an immunobinding-fluorescence quantitative polymerase chain reaction (PCR) combination, and evaluating infectivity and transmissibility of the SARS-CoV-2. The method is suitable for evaluating the replication and transmission of the SARS-CoV-2 in a patient infected with the SARS-CoV-2 during a treatment process and the infectivity of the SARS-CoV-2 carried by a patient with relapse symptoms after recovery.

MRNA FOR SARS-COV-2 S PROTEIN AND USE THEREOF

NºPublicación:  EP4560021A1 28/05/2025
Solicitante: 
SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD [CN]
Shenzhen Shenxin Biotechnology Co., Ltd
EP_4560021_A1

Resumen de: EP4560021A1

The present invention relates to an RNA encoding the S protein of SARS-COV-2, a vaccine comprising the RNA, and uses thereof. The present invention also relates to a universal polynucleotide molecule comprising a 5'-UTR and/or a 3'- UTR, and a nucleic acid sequence encoding a protein and/or polypeptide of interest, and optionally comprising a polyA.

PREFUSION-STABILIZED SARS-COV-2 SPIKE S2 SUBUNIT AS ANTIGEN FOR BROAD PAN-CORONAVIRUS VACCINES

NºPublicación:  WO2025106792A1 22/05/2025
Solicitante: 
LA JOLLA INST FOR IMMUNOLOGY [US]
LA JOLLA INSTITUTE FOR IMMUNOLOGY
WO_2025106792_A1

Resumen de: WO2025106792A1

Provided herein is a stable mutant coronavirus spike protein stem domain in a prefusion conformation comprising: an S2 subunit only, that has been modified to comprise; at least one additional intra-monomeric disulfide bond that stabilizes the S2 subunit; and 1, 2, 3, 4, or 5 proline mutations for greater trimeric stability, wherein the mutant coronavirus pre-fusion, S2-only spike protein maintains the prefusion conformation. Coronavirus is SARS, MERS, 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta), SARS-CoV-2, existing variants, or an emerging variant thereof.

SARS-COV-2 SARS-COV-2 IMMUNOGENIC COMPOSITIONS

NºPublicación:  KR20250071877A 22/05/2025
Solicitante: 
바이오엔테크에스이
KR_20250071877_PA

Resumen de: WO2025106738A1

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.

ANTIGEN BINDING MOLECULES TARGETING SARS-COV-2

NºPublicación:  AU2023375894A1 22/05/2025
Solicitante: 
GENERATE BIOMEDICINES INC
GENERATE BIOMEDICINES, INC
AU_2023375894_A1

Resumen de: AU2023375894A1

The disclosure provides, in various embodiments, polypeptides (e.g, antibodies and antigen binding fragments thereof) that specifically bind to receptor binding domains (RBDs) of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).

Pharmaceutical Compositions and Methods for Treating Covid

NºPublicación:  US2025161262A1 22/05/2025
Solicitante: 
BARANOWITZ STEVEN [US]
BARANOWITZ Steven
WO_2023150067_A1

Resumen de: US2025161262A1

Pharmaceutical compositions and methods for preventing, treating, relieving, or ameliorating symptoms of coronavirus infection, including COVID-19 and variants thereof, including treating or preventing severe illness from corona vims infection, comprising the administration of IMPDH inhibitors and/or restricted diets of guanosine-containing nucleosides or nucleotides.

Methods of Treating Covid-Related Disorders

NºPublicación:  US2025161308A1 22/05/2025
Solicitante: 
ATHIRA PHARMA INC [US]
Athira Pharma, Inc
JP_2025508768_A

Resumen de: US2025161308A1

The present disclosure relates to a method of treating long-term sequelae of infection with SARS-CoV-2, also known as long COVID. More particularly, it discloses the method of treating long COVID, the method comprising administering to a patient in need thereof a therapeutically effective amount of a HGF/MET positive modulating agent.

Deuterium-Enriched Nirmatrelvir as SARS-CoV-2 Mpro Inhibitor for the Treatment of COVID-19

NºPublicación:  US2025163026A1 22/05/2025
Solicitante: 
DHANOA DALJIT SINGH [US]
Dhanoa Daljit Singh

Resumen de: US2025163026A1

The present invention is concerned with novel deuterium-enriched compounds of the general chemical structural formula I., and pharmaceutically acceptable salts, compositions, and methods of use thereof,wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, R25 are independently D (deuterium), H (hydrogen). The compounds of general chemical formula I are novel deuterium-enriched analogs of the SARS-CoV-2 main protease (MPro) inhibitor Nirmatrelvir for the treatment of COVID-19 and related diseases caused by various coronaviruses and their variants.

FUSION PROTEIN AND USE THEREOF

NºPublicación:  US2025163107A1 22/05/2025
Solicitante: 
SHANXI JINBO BIO PHARMACEUTICAL CO LTD [CN]
FUDAN UNIV [CN]
SHANXI JINBO BIO-PHARMACEUTICAL CO.,LTD,
FUDAN UNIVERSITY
JP_2025514561_A

Resumen de: US2025163107A1

Provided are a fusion protein and use thereof. Provided is a fusion protein, comprising a trimerization block and an immunogenic block which are connected by a linker, wherein the trimerization block comprises one or more of repeat units set forth in SEQ ID NO. 1; the immunogenic block is an immunogenic protein of a pathogen, for example, being selected from a coronavirus RBD block, an HIV membrane protein or an influenza virus hemagglutinin protein, and immunogenic fragments thereof. Compared with an immunogen monomer, the trimer can generate a higher neutralizing antibody level, does not induce a strong antibody against the trimerization block in a human body, and can promote the immune response of the organism to be focused on the immunogenic block.

INTERFERON-PRODUCING UNIVERSAL SARBECOVIRUS VACCINES, AND USES THEREOF

NºPublicación:  US2025161433A1 22/05/2025
Solicitante: 
CENTRE FOR VIROLOGY VACCINOLOGY AND THERAPEUTICS LTD [HK]
Centre for Virology, Vaccinology and Therapeutics Limited

Resumen de: US2025161433A1

The present invention relates to universal sarbecovirus vaccines that specifically express an interferon. This live universal sarbecovirus vaccine elicits mucosal immunity and heterotypic immunity against various sarbecoviruses, including SARS-CoV-1, SARS-CoV-2, and its variants. Interferon directly encoded from the genome of the live universal sarbecovirus overrides the virus-induced “delayed type-I interferon”, resulting in enhancement of mucosal T cell responses. The present invention further relates to uses of the vaccines for the preparation of pharmaceutical compositions, methods of treating or preventing viral infections, and kits comprising the vaccines.

ATTENUATED SARS-COV-2

NºPublicación:  US2025161431A1 22/05/2025
Solicitante: 
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
Board of Regents, The University of Texas System
WO_2023154105_PA

Resumen de: US2025161431A1

This composition of this invention is comprised of live attenuated SARS-CoV-2 constructs as vaccines or research tools. Described herein is a highly attenuated SARS-CoV-2 with deleted accessory proteins and modified transcriptional regulator sequences (TRS) that can serve as a live-attenuated vaccine platform and a BSL-2 experimental system. Certain embodiments are directed to a live attenuated SARS-CoV-2 having a modified transcriptional regulatory sequence (TRS) and a deletion of one or more open reading frames selected from ORF3a, ORF3, ORF6, ORF7, and/or ORFS.

USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT OF COVID-19 INFECTIONS AND PROGNOSIS OF SEVERE DISEASE

NºPublicación:  US2025164510A1 22/05/2025
Solicitante: 
GAMMA DIAGNOSTICS INC [US]
Gamma Diagnostics Inc
WO_2023163797_PA

Resumen de: US2025164510A1

A method of assessing a COVID-19 infection in a person, the method comprising analysing the concentration or levels of one or more biomarkers in a biological sample from a person, wherein the one or more biomarkers comprises γ′ fibrinogen, and wherein concentration or levels of γ′ fibrinogen are elevated in a biological sample from a person infected with COVID-19 and can be used for predicting COVID-19 disease severity and/or for making a prognosis of severe COVID-19 disease in a person infected with COVID-19.

MICROWAVE DISINFECTION PROTOCOL OPTIMISED FOR THE DESTRUCTION/ INACTIVATION OF SARS-COV-2 AND H1N1 VIRUSES

NºPublicación:  US2025161518A1 22/05/2025
Solicitante: 
ELETTR S P A [IT]
ELETTRONICA S.P.A
JP_2025506276_PA

Resumen de: US2025161518A1

The invention concerns a microwave disinfection device (2) configured to destroy/inactivate the SARS-COV-2 and H1N1 viruses and comprising a microwave irradiation section (22) configured to: irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHZ and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS

NºPublicación:  WO2025106738A1 22/05/2025
Solicitante: 
BIONTECH SE [DE]
BIONTECH SE
WO_2025106738_A1

Resumen de: WO2025106738A1

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.

CORONAVIRUS VACCINE

NºPublicación:  WO2025106754A1 22/05/2025
Solicitante: 
BIONTECH SE [DE]
BIONTECH SE
WO_2025106754_A1

Resumen de: WO2025106754A1

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

HOP DERIVED COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES CAUSED BY CORONAVIRUSES

NºPublicación:  WO2025104281A1 22/05/2025
Solicitante: 
CENTRE NAT RECH SCIENT [FR]
INST NAT SANTE RECH MED [FR]
PASTEUR INSTITUT [FR]
UNIV STRASBOURG [FR]
UNIV LILLE [FR]
CENTRE HOSPITALIER UNIV DE LILLE [FR]
UNIV HAUTE ALSACE [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE,
INSTITUT PASTEUR DE LILLE,
UNIVERSITE DE STRASBOURG,
UNIVERSITE DE LILLE,
CENTRE HOSPITALIER UNIVERSITAIRE DE LILLE,
UNIVERSITE DE HAUTE-ALSACE
WO_2025104281_A1

Resumen de: WO2025104281A1

The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses. The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2. The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.

IMMUNOGENIC COMPOSITION AND USES THEREOF

NºPublicación:  WO2025106425A1 22/05/2025
Solicitante: 
UNIV FLORIDA [US]
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
WO_2025106425_A1

Resumen de: WO2025106425A1

The disclosure provides a composition comprising a nucleic acid encoding a human alpha coronavirus (HCoV) receptor binding domain (RBD) peptide and a severe acute respiratory syndrome coronavirus 2 (SCoV2) RBD peptide.

HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19

NºPublicación:  ES3019940T3 21/05/2025
Solicitante: 
ATEA PHARMACEUTICALS INC
ATEA Pharmaceuticals, Inc
CN_119139338_PA

Resumen de: PH12022552054A1

The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

--2 SARS-CoV-2 universal recombinant antigen polypeptides polynucleotides and uses thereof

NºPublicación:  KR20250071176A 21/05/2025
Solicitante: 
대한민국질병관리청국립보건연구원장고려대학교산학협력단
KR_20250071176_A

Resumen de: KR20250071176A

본 발명은 사스-코로나바이러스-2 (SARS-CoV-2) 범용 항원 아미노산 서열로 이루어진 폴리펩타이드 및 상기 폴리펩타이드를 암호화하는 폴리뉴클레오타이드에 관한 것이며, 상기 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 SARS-CoV-2 감염증 예방용 백신 조성물 및 예방 또는 치료용 약학적 조성물에 관한 것이다. 본 발명은 와일드 타입의 SARS-CoV-2 및 현존하는 SARS-CoV-2 변이주뿐만 아니라 가상의 SARS-CoV-2 변이주에까지 대응할 수 있는 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드의 특정 위치의 아미노산을 치환함으로써 구조 안정성을 더욱 향상시킨 SARS-CoV-2 범용 항원 폴리펩타이드 및 이를 암호화하는 폴리뉴클레오타이드를 제공한다. 또한 본 발명은 상기 SARS-CoV-2 범용 항원 폴리펩타이드 또는 폴리뉴클레오타이드를 유효성분으로 포함하는 백신 및 약학적 조성물을 제공한다.

HOP DERIVED COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES CAUSED BY CORONAVIRUSES

NºPublicación:  EP4556004A1 21/05/2025
Solicitante: 
CENTRE NAT RECH SCIENT [FR]
INST NAT SANTE RECH MED [FR]
PASTEUR INSTITUT [FR]
UNIV STRASBOURG [FR]
UNIV LILLE [FR]
CENTRE HOSPITALIER UNIV DE LILLE [FR]
UNIV HAUTE ALSACE [FR]
Centre National de la Recherche Scientifique,
Institut National de la Sant\u00E9 et de la Recherche M\u00E9dicale,
Institut Pasteur de Lille,
Universit\u00E9 de Strasbourg,
Universit\u00E9 de Lille,
Centre Hospitalier Universitaire de Lille,
Universit\u00E9 de Haute Alsace
EP_4556004_A1

Resumen de: EP4556004A1

The present invention belongs to the field of compounds for use in therapeutic treatment, and more particularly hop derived compounds for use in the treatment of diseases caused by coronaviruses.The main field of application is human health, through the development of new active beta-acid-type antivirals against SARS-CoV-2The present invention relates to hop derived compounds according to the invention for use in the treatment of diseases caused by a virus chosen from coronaviruses belonging to the Coronaviridae family.

SARS-COV-2 NEUTRALIZING ANTIBODY

NºPublicación:  EP4556490A1 21/05/2025
Solicitante: 
SCRIPPS KOREA ANTIBODY INST [KR]
Scripps Korea Antibody Institute
EP_4556490_PA

Resumen de: EP4556490A1

The present disclosure relates to a neutralizing antibody against SARS-coronavirus 2 (SARS-CoV2) or a variant virus thereof, or an antigen-binding fragment thereof. Since the neutralizing antibody of the present disclosure has inhibitory effect against SARS-coronavirus 2 and variants thereof (e.g., Delta variant, Omicron variant, etc.), it can be usefully used for prevention or treatment of infection by SARS-coronavirus 2 or variants thereof.

SARS-COV-2 VACCINE BOOSTER COMPOSITION

NºPublicación:  EP4556021A1 21/05/2025
Solicitante: 
SK BIOSCIENCE CO LTD [KR]
SK Bioscience Co., Ltd
EP_4556021_A1

Resumen de: EP4556021A1

The present disclosure provides a composition for inducing or maintaining an immune response against SARS-CoV-2 virus.

Personal and reusable infection status passport device that is configured to test for Covid-19 and infectious disease

NºPublicación:  US12308098B1 20/05/2025
Solicitante: 
BISCHOFF WALTER GEORGE [US]
Bischoff Walter George
US_12308098_PA

Resumen de: US12308098B1

A personal and reusable infection status passport device is disclosed that is configured to test for Covid-19 and infectious disease using photo and color analysis. The personal and reusable infection status passport device provides a supervisory testing unit/system to ensure testing is current and accurate. The quick and ease of use will allow for frequent testing so the individual will know their status without spending hours at a clinic or large sums of money on many single use tests. The test units are easier to produce and use with the main device. The device is capable of using a time stamp to ensure the test is current. The included processor and software will create a “status passport” system that will allow users to share their Covid-19 status as needed to comply with state, federal, local, and OSHA.

SARS-CoV-2 RBD HR2 - Use of HR2 peptide-fusion human antibodies for targeting the SARS-CoV-2 RBD and derivatives thereof

NºPublicación:  KR20250069453A 19/05/2025
Solicitante: 
국민대학교산학협력단
KR_20250069453_PA

Resumen de: KR20250069453A

본 발명은 SARS-CoV-2 RBD 표적 HR2 펩타이드-융합 인간 항체의 활용 및 용도에 관한 것이다. 보다 구체적으로, 본 발명은 헵타드 반복 2 펩타이드(Heptad Repeat 2 Peptide, HR2) 및 코로나 바이러스의 수용체 결합 도메인과 특이적으로 결합하는 항체 또는 항원 결합 단편을 포함하는 단백질 복합체 및 이를 유효성분으로 포함하는, 코로나 바이러스 감염증의 치료용 약제학적 조성물에 관한 것이다. 본 발명의 상기 단백질 복합체는 잘 보존된 영역인 헵타드 반복 2 펩타이드를 코로나바이러스의 RBD 특이적 항체와 결합한 결과, 다양한 SARS-CoV-2 바이러스 변종에 대하여 독성없이 향상된 중화능을 나타내므로, 지속적으로 진화하는 SARS-CoV-2 변종에 효과적으로 대항할 수 있는 치료제 플랫폼으로써 유용하게 사용될 수 있다.

COMBINATION EXOSOMAL IMMUNOGENIC COMPOSITIONS AND METHODS

NºPublicación:  AU2023353862A1 15/05/2025
Solicitante: 
CAPRICOR INC
CAPRICOR, INC
AU_2023353862_PA

Resumen de: AU2023353862A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants and other respiratory viruses that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein, engineered nucleocapsid protein, engineered hemagglutinin protein, and/or engineered respiratory syncytial virus prefusion or fusion (RSV F) protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display, nucleocapsid-display, hemagglutinin-display, and/or RSV F-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple respiratory viruses and variants.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

NºPublicación:  WO2025098545A1 15/05/2025
Solicitante: 
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I [CZ]
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V. V. I
WO_2025098545_PA

Resumen de: WO2025098545A1

The invention relates to small molecule inhibitors of formula (I) targeting the nsp14 protein of SARS- CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

LYOPHILIZED MRNA-LNP VACCINE PRODUCTS

NºPublicación:  WO2025098237A1 15/05/2025
Solicitante: 
IMMORNA HANGZHOU BIOTECHNOLOGY CO LTD [CN]
IMMORNA (HANGZHOU) BIOTECHNOLOGY CO., LTD
WO_2025098237_A1

Resumen de: WO2025098237A1

A lyophilized RNA-LNP (e.g., mRNA-lipid nanoparticle), a method of making or using the same, such as for vaccination using an mRNA encoding an antigenic vaccine (e.g., SARS-CoV-2).

CORONAVIRUS VACCINE

NºPublicación:  US2025152699A1 15/05/2025
Solicitante: 
CUREVAC SE [DE]
CureVac SE
US_2024277830_PA

Resumen de: US2025152699A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

AUTOLOGOUS CELL BASED SARS-COV-2 VACCINES

NºPublicación:  US2025152697A1 15/05/2025
Solicitante: 
ORGENESIS INC [US]
Orgenesis Inc
WO_2023137370_PA

Resumen de: US2025152697A1

Disclosed herein are multi-antigenic autologous, cell-based SARS-CoV-2 vaccines comprising autologous antigen presenting cells (APCs) displaying at least two different SARS-CoV-2 antigens. These vaccines can be used to prevent SARS-CoV-2 infection or COVID-19. Further disclosed are methods for producing and using the vaccines.

ANTIVIRAL SULFATED CHITOSAN DERIVATIVES

NºPublicación:  US2025152618A1 15/05/2025
Solicitante: 
CONSEJO SUPERIOR DE INVESTIG CIENTIFICAS CSIC [ES]
UNIV DE VALENCIA [ES]
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC),
UNIVERSITAT DE VAL\u00C8NCIA
WO_2023156349_PA

Resumen de: US2025152618A1

The invention relates to sulfated chitosan derivatives of formula (I), wherein the meanings for the various substituents are as disclosed in the description, for their use in the treatment and/or prevention of a viral infection, particularly wherein the viral infection is caused by SARS-CoV-2 such as COVID-19 or RSV.

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

NºPublicación:  US2025154230A1 15/05/2025
Solicitante: 
UNIV ZU KOELN [DE]
UNIVERSIT\u00C4T ZU K\u00D6LN
JP_2024542793_A

Resumen de: US2025154230A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

MODIFIED PRIMARY IMMUNE CELLS FOR INDUCTION OR ENHANCEMENT OF IMMUNOTHERAPY

NºPublicación:  US2025152710A1 15/05/2025
Solicitante: 
RILEY JAMES L [US]
THE WISTAR INST OF ANATOMY AND BIOLOGY [US]
THE TRUSTEES OF THE UNIV OF PENNSYLVANIA [US]
RILEY James L,
The Wistar Institute of Anatomy and Biology,
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
WO_2023154761_PA

Resumen de: US2025152710A1

Provided herein are compositions with an augmented capacity to mediate ADCC. These compositions include chimeric NK cells—called “Nukes” (NK Enhancement Strategy) that express CD64 Fc receptor from an exogenous nucleic acid molecule, the NK cells having antibodies bound thereto. Methods of using these cells for treatment of HIV, cancer, SARS-COV-2, and other diseases are provided.

USE OF AMINOPYRIDINE, IN PARTICULAR AMIFAMPRIDINE, FOR THE TREATMENT OF A VIRALLY-ASSOCIATED FATIGUE

NºPublicación:  US2025152566A1 15/05/2025
Solicitante: 
BOEHMEKE THOMAS [DE]
BOEHMEKE Thomas

Resumen de: US2025152566A1

The present invention relates to a new use of an Aminopyridine, such as Pyridine-3,4-diamine, a derivative thereof and/or of a physiologically tolerable salt thereof for the prevention and/or treatment of a fatigue, which is associated with a viral infection, preferably by SARS-CoV-2. In particular for the treatment of fatigue in connection with a “post-COVID phase” and the “long COVID-19 syndrome”.

COMPOSITIONS AND METHODS FOR COVID-19 TREATMENT

NºPublicación:  US2025152613A1 15/05/2025
Solicitante: 
101 THERAPEUTICS LTD [IL]
101 THERAPEUTICS LTD
JP_2025502175_PA

Resumen de: US2025152613A1

Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).

COMPOSITION FOR POC PCR

NºPublicación:  US2025155436A1 15/05/2025
Solicitante: 
PROCOMCURE BIOTECH GMBH [AT]
PROCOMCURE BIOTECH GMBH
CH_719425_A2

Resumen de: US2025155436A1

Liquid composition for the preparation of a biological sample for methods for assaying for the presence of SARS-COV-2 or genetic variations (mutant) of SARS-COV-2 wildtype in said sample by POC PCR comprising: • a) a chaotropic salt, preferably guanidinium thiocyanate, in a concentration ranging from 1 to 90 mM and • b) optionally one or more RNAse inhibitor.

DEVICE AND METHOD FOR PATHOGEN DETECTION

NºPublicación:  US2025155438A1 15/05/2025
Solicitante: 
KING ABDULAZIZ UNIV [SA]
King Abdulaziz University

Resumen de: US2025155438A1

Systems and methods are disclosed herein for pathogen detection employing a lateral flow assay (LFA) device or ELISA assay, e.g. for detecting SARS-COV-2, the virus that causes COVID-19, in a sample. The LFA device includes a nitrocellulose membrane mounted on a solid support, a sample pad for receiving a sample, a conjugate pad containing gold nanoparticles conjugated to heavy chain antibodies (HcAbs), and an absorbent pad at the end of the device.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CONONAVIRUS SARS-COV-2

NºPublicación:  US2025154231A1 15/05/2025
Solicitante: 
RQBIO COVID LTD [GB]
RQBIO COVID LIMITED
JP_2025507595_A

Resumen de: US2025154231A1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

NOVEL REOVIRUS-BASED VACCINE PLATFORM AND USE THEREOF

NºPublicación:  US2025154204A1 15/05/2025
Solicitante: 
VIROCURE INC [KR]
VIROCURE, INC
WO_2023048532_PA

Resumen de: US2025154204A1

The present invention relates to a novel reovirus-based vaccine platform, and confirmed that a part of the S1 gene of reovirus can be replaced with various exogenous epitope-encoding genes, and a recombinant reovirus manufactured according to the present invention not only can infect target cells and induce the expression of the epitope, but also can effectively prevent and treat diseases related to the epitope by activating the immune function of immune cells against the epitope. When using the reovirus-based vaccine platform of the present invention, vaccines containing various epitopes can be manufactured through relatively simple genetic manipulation technology, and can be administered in various ways including oral administration, so it can be utilized for the prevention and treatment of various infectious diseases including SARS-CoV-2 virus infection, and cancer.

ANTIVIRAL NUCLEIC ACIDS AND COMPOSITIONS

NºPublicación:  AU2023366039A1 15/05/2025
Solicitante: 
GRIFFITH UNIV
GRIFFITH UNIVERSITY
AU_2023366039_A1

Resumen de: AU2023366039A1

The present invention relates generally to compositions and methods for inhibiting the replication of coronaviruses and treating diseases caused by coronavirus infection. More specifically, the invention provides nucleic acids capable of inhibiting coronavirus (e.g. SARS-CoV-2) replication and their use in treating patients infected by the virus.

EXTRACELLULAR VESICLE COMPOSITION FOR USE IN THE TREATMENT OF LONG COVID

NºPublicación:  WO2025101653A1 15/05/2025
Solicitante: 
DIRECT BIOLOGICS LLC [US]
DIRECT BIOLOGICS, LLC
WO_2025101653_PA

Resumen de: WO2025101653A1

Long COVID or Post Acute Sequelae of COVID-19 (PASC), is a prolonged, debilitating syndrome that follows acute SARS-CoV-2 infection in >10% of cases. Human bone marrow mesenchymal stem cell derived extracellular vesicles (hBM-MSC EVs) can present a new therapeutic option.

HUMANIZED ACE2-EXPRESSING TRANSGENIC MOUSE SUSCEPTIBLE TO SARS-COV-2 VIRUS INFECTION AND METHOD FOR PRODUCING SAME

NºPublicación:  WO2025100882A1 15/05/2025
Solicitante: 
SEOUL NATIONAL UNIV R&DB FOUNDATION [KR]
\uC11C\uC6B8\uB300\uD559\uAD50\uC0B0\uD559\uD611\uB825\uB2E8
WO_2025100882_A1

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

SARS-CoV-2 ACE2 Transgenic mouse expressing humanized ACE2 susceptible for SARS-CoV-2 virus infection and production method therefor

NºPublicación:  KR20250067048A 14/05/2025
Solicitante: 
서울대학교산학협력단
WO_2025100882_A1

Resumen de: WO2025100882A1

The present invention discloses: a humanized ACE2-expressing transgenic mouse susceptible to SARS-CoV-2 virus infection, the mouse being obtained by applying a CRISPR system; and a method for producing same. The humanized ACE2-expressing transgenic mouse according to the present invention reflects the severity of symptoms, mortality patterns, and the like according to age, sex, viral infection dose, and the like, as observed in human COVID-19 cases, and reproduces immunopathological characteristics of SARS-CoV-2 infection in the lungs without viral replication or lesions in the brain, and thus can be effectively used to understand the pathogenesis of SARS-CoV-2 and to develop vaccines or therapeutic agents.

NUCLEOSIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST CORONAVIRUSES

NºPublicación:  EP4553080A1 14/05/2025
Solicitante: 
USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I [CZ]
Ustav Organicke Chemie a Biochemie AV CR, v.v.i
EP_4553080_PA

Resumen de: EP4553080A1

The invention relates to small molecule inhibitors of formula (I) targeting the nspl4 protein of SARS-CoV-2 and other coronaviruses, for use as antiviral agents directly targeting viral proteins.

USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS

NºPublicación:  EP4553084A2 14/05/2025
Solicitante: 
ETHRIS GMBH [DE]
Ethris GmbH
EP_4553084_A2

Resumen de: EP4553084A2

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

NºPublicación:  KR20250064725A 12/05/2025
Solicitante: 
대한민국질병관리청국립보건연구원장주아이랩

Resumen de: KR20250064725A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

2 A Immunoglobulin A antibody for neutralizing SARS coronavirus 2 spike antigen and uses thereof

NºPublicación:  KR20250064724A 12/05/2025
Solicitante: 
대한민국질병관리청국립보건연구원장주아이랩

Resumen de: KR20250064724A

본 발명은 사스 코로나바이러스 2 스파이크 항원에 특이적으로 결합하는 이뮤노글로불린 A 항체를 제조하여 이를 사스 코로나바이러스 2 검출 또는 진단 용도로 사용하거나 사스 코로나바이러스 2 중화 효과를 기반으로 사스 코로나바이러스 2 감염질환 예방 또는 치료하기 위해 사용하는 용도에 관한 것이다.

SARS-CoV-2 USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

NºPublicación:  KR20250063018A 08/05/2025
Solicitante: 
포항공과대학교산학협력단대한민국질병관리청국립보건연구원장
US_2025134989_A1

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

NºPublicación:  AU2023375471A1 08/05/2025
Solicitante: 
RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL
RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL
AU_2023375471_PA

Resumen de: AU2023375471A1

Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

HUMAN MONOCLONAL ANTIBODIES THAT BROADLY TARGET CORONAVIRUSES

NºPublicación:  US2025145690A1 08/05/2025
Solicitante: 
THE U S A AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES [US]
The U.S.A., as represented by the Secretary, Department of Health and Human Services
JP_2025506172_A

Resumen de: US2025145690A1

Disclosed are monoclonal antibodies and antigen binding fragments that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection. In addition, disclosed are methods for detecting a coronavirus in a biological sample, using the disclosed antibodies.

HUMAN MONOCLONAL ANTIBODIES TARGETING THE S2 SUBUNIT OF THE SARS-COV-2 SPIKE PROTEIN

NºPublicación:  US2025145691A1 08/05/2025
Solicitante: 
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM,
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
WO_2023159061_A2

Resumen de: US2025145691A1

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

CHIMERA MOLECULES FOR SARS-COV-2 AND METHODS OF USE

NºPublicación:  US2025145692A1 08/05/2025
Solicitante: 
WANG SHAOXIAO [US]
WANG SIMON [US]
WANG YI [US]
Wang Shaoxiao,
Wang Simon,
Wang Yi

Resumen de: US2025145692A1

The subject matter described herein is directed to a chimera molecule such as a polypeptide or protein chimera useful for treating or preventing a viral infection or reducing the severity, incidence, or transmissibility of a viral infection, to nucleic acid molecules encoding the polypeptide or protein chimera, and to pharmaceutical compositions containing them. Also, methods of generating such antiviral polypeptide or protein chimera, of generating nucleic acid molecules encoding the antiviral polypeptide or protein chimera, and of generating pharmaceutical compositions containing the same, and methods of using the same for treatment or prevention of a SARS-CoV-2 infection, or to reduce the severity, incidence, or transmissibility of a of a SARS-CoV-2 infection, are described.

METHODS AND DEVICES FOR RAPID DETECTION OF COVID-19 AND OTHER PATHOGENS

NºPublicación:  US2025144636A1 08/05/2025
Solicitante: 
KHALIFA UNIV OF SCIENCE AND TECHNOLOGY [AE]
Khalifa University of Science and Technology
US_2022258167_A1

Resumen de: US2025144636A1

A device and method for detecting COVID-19 and other pathogens includes a sample compartment contained within an interior of the device and having multiple apertures for releasably receiving one or more test tubes containing a biological sample. A bottom portion of the test tube is contained within the interior of the device and a top portion of the test tube is exposed to atmosphere. The biological sample is lysed using the device; the lysed sample is mixed with one or more primers and then amplification (RT-LAMP) is performed using the device. A thermally conductive material on or in proximity to the sample compartment can facilitate precise heating of the compartment and sample. A thermally insulative material can be inside the interior of the housing. Multiple samples can be tested simultaneously. The results can be interpreted by a color change of the sample. The device is efficient, portable, reliable, and re-usable.

PEPTIDE

NºPublicación:  US2025145667A1 08/05/2025
Solicitante: 
QUEEN MARY UNIV OF LONDON [GB]
BARTS HEALTH NHS TRUST [GB]
QUEEN MARY UNIVERSITY OF LONDON,
BARTS HEALTH NHS TRUST
WO_2023099920_A1

Resumen de: US2025145667A1

The present invention relates to peptides derived from COVID-19 virus envelope protein and spike protein. The invention further relates to polynucleotides and vectors encoding said peptides, and antibodies and chimeric antigen receptors that bind to said peptides. The invention also relates to methods of diagnosis and prediction of conditions in a subject which leverage recognition of said peptides, such as by antigen-specific T cells.

COMPOSITE PARTICLE FORMULATIONS AND APPLICATIONS THEREOF

NºPublicación:  US2025144040A1 08/05/2025
Solicitante: 
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
WO_2023141278_PA

Resumen de: US2025144040A1

Composite particle including the following: (1) a nanocrystal of an organic compound, and (2) a block copolymer associated with one or more surfaces of the nanocrystal of an organic compound. The organic compound, in some embodiments, is a pharmaceutical compound, a therapeutic compound, and/or a bioactive compound. The block copolymer may be a block copolymer with at least one hydrophilic poly(2-oxazoline) block. Pharmaceutical compositions may include these composite particles. The pharmaceutical compositions may include a dispersion that has an aqueous or aqueous-based continuous phase and a dispersed phase that includes the composite particles. The dispersion may be administered to sick patients, including those diagnosed with or exhibiting symptoms of COVID-19. For example, the dispersion may be aerosolized, and a patient may inhale the aerosol.

ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION

NºPublicación:  US2025144119A1 08/05/2025
Solicitante: 
EIRGEN PHARMA LTD [IE]
Eirgen Pharma Ltd
JP_2023520591_A

Resumen de: US2025144119A1

Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

TETANUS VACCINE PLATFORM FOR EMBEDDING COVID-19 VACCINE

NºPublicación:  US2025144201A1 08/05/2025
Solicitante: 
PRIME BIO INC [US]
Prime Bio, Inc
KR_20240031857_PA

Resumen de: US2025144201A1

A method of immunizing against COVID-19 by administering a recombinant SARS-CoV2 protein-based vaccine, developed by either embedding the epitopes/domains, or chemically attaching, to an already established vaccine candidate, e.g., a detoxified recombinant tetanus neurotoxin (DrTeNT). The developed vaccine will have three novel contributions compared to the present vaccine technology: a) providing a novel and very effective vaccine platform; b) priming with DrTeNT will prepare the host immune system for better response; and c) oral delivery of the vaccine candidate with a group of neurotoxin binding proteins (NAPs) from Clostridium sp. A Detoxified recombinant tetanus neurotoxin (DrTeNT) is prepared by mutation of the active site amino acid residues is an effective vaccine candidate, and is used for embedding epitopes of SARS-CoV-2 virus protein for vaccination against Covid-19. DrTeNT is a risk-free vaccine, free of formalin or any other chemical adjuvants.

COMPOSITIONS AND METHODS FOR FcRn-TARGETED INTRANASAL CORONAVIRUS VACCINATION

NºPublicación:  US2025144199A1 08/05/2025
Solicitante: 
UNIV OF MARYLAND COLLEGE PARK [US]
UNIVERSITY OF MARYLAND, COLLEGE PARK
WO_2023154402_PA

Resumen de: US2025144199A1

The present disclosure relates generally to novel recombinant coronavirus-based fusion proteins (“RBDs-IgG Fc protein” and “RBDs protein”) and vaccine compositions using the same, in which the fusion proteins comprise tandemly arranged coronaviruses receptor binding domains (RBDs). The present disclosure further provides methods and kits for immunizing a subject using the compositions.

USE OF VE607 FOR THE TREATMENT OF SARS-COV-2 INFECTIONS AND RELATED DISEASES

NºPublicación:  US2025144087A1 08/05/2025
Solicitante: 
FINZI ANDRES [CA]
PAZGIER MARZENA [US]
SMITH III AMOS B [US]
DING SHILEI [CA]
MOTHES WALTER [US]
BARON CHRISTIAN [CA]
YANG DEREK [US]
MOHAMMADI MOHAMMADJAVAD [US]
ABRAMS CAMERON [US]
FINZI Andr\u00E9s,
PAZGIER Marzena,
SMITH, III Amos B,
DING Shilei,
MOTHES Walter,
BARON Christian,
YANG Derek,
MOHAMMADI Mohammadjavad,
ABRAMS Cameron
WO_2023147658_PA

Resumen de: US2025144087A1

The present application relates to the use of 3,3′-(1,3-phenylenebis(oxy))bis(1-(piperidin-1-yl)propan-2-ol (VE607) or a pharmaceutically acceptable salt thereof for the inhibition of SARS-CoV-2 and/or management of COVID-19.

THERAPEUTIC TREATMENT FOR THE CORONAVIRUS DISEASE COVID-19

NºPublicación:  US2025144163A1 08/05/2025
Solicitante: 
MOLLICK PETER JOSEPH [US]
Mollick Peter Joseph

Resumen de: US2025144163A1

A therapeutic treatment for the treatment of COVID-19 disease, the treatment to be initiated soon after and preferably within approximately twenty four hours after a patient develops the first signs of symptoms comprising but not limited to individually or in combination thereof fever, headache, sore joints, cough, fatigue, chills. The treatment consists of the oral administration of an extracted component or a combination of extracted components of an herb thyme leaf also know as common thyme (Thymus Vulgaris). The treatment is thought to inhibit the replication and activity of the virus allowing the patient to regain normal health and assist in developing immunity to the virus. The treatment is not known to completely eliminate the virus from the patient therefore resulting in the patient possibly developing the same or different symptoms of the disease a second, or more times requiring additional treatments of the disclosed thyme therapeutic treatment.

BETA-CORONAVIRUS FUSION RECOMBINANT PROTEIN, AND PREPARATION METHOD AND APPLICATION THEREOF

NºPublicación:  US2025144062A1 08/05/2025
Solicitante: 
BIOPHARMAGEN CORP FANGZHOU SUZHOU [CN]
BIOPHARMAGEN CORP., FANGZHOU SUZHOU
CN_116751305_PA

Resumen de: US2025144062A1

Disclosed is a betacoronavirus fusion recombinant protein, comprising an RBD region and a COVID19-SF5 fragment of a spike protein of SARS-COV-2 (COVID-19), and an amino acid sequence of the COVID19-SF5 fragment is an 880th amino acid to a 1084th amino acid of the S protein of the novel coronavirus COVID-19. According to the invention, a constant conserved fragment (COVID19-SF5) and a receptor binding domain (RBD) fragment are fused and expressed to provide a more-effective constant universal vaccine candidate recombinant fusion protein for such type of coronavirus, thus providing broader and better protection measures from two standpoints of inhibiting receptor recognition and providing universal protection.

SARS-CoV-2 SARS-CoV-2 Composition For Detecting SARS-CoV-2 and Method of Detecting SARS-CoV-2 Using the Same

NºPublicación:  KR20250059620A 07/05/2025
Solicitante: 
재단법인대구경북첨단의료산업진흥재단

Resumen de: KR20250059620A

본 발명은 프라이머 쌍 및 프로브를 포함하는 신종 코로나바이러스 19(SARS-CoV-2) 검출용 조성물 및 이를 이용한 신종 코로나바이러스 19(SARS-CoV-2) 검출방법에 관한 것으로, 보다 상세하게는 재조합효소 중합효소 증폭(Recombinase Polymerase Amplification; RPA)방법을 이용한 SARS-CoV-2 검출용 조성물, 키트 및 이를 이용한 SARS-CoV-2 검출방법에 관한 것이다.

PHARMACEUTICAL COMPOSITION FOR RESISTING INFECTION WITH SARS-COV-2 OR MUTANT THEREOF, AND COMBINED DRUG THEREOF

NºPublicación:  EP4549452A1 07/05/2025
Solicitante: 
WESTVAC BIOPHARMA CO LTD [CN]
WestVac Biopharma Co., Ltd
EP_4549452_A1

Resumen de: EP4549452A1

Provided are a pharmaceutical composition for resisting infection with SARS-CoV-2 or a mutant thereof, and a combined drug thereof. To solve the problem of the lack of effective prevention and treatment drugs for infection with SARS-CoV-2 or a mutant virus thereof, provided are a recombinant protein vaccine and/or an adenovirus vaccine for preventing and/or treating an infection with SARS-CoV-2 or a mutant thereof, and in particular, provided are a nasal spray administration compound formulation containing active ingredients of two vaccines, i.e., a recombinant protein vaccine and an adenovirus vaccine, and a combination of the two vaccines for nasal spray administration, which can induce generation of strong antibody and cellular immune responses in vivo and block the binding of a protein S of SARS-CoV-2 to an ACE2 receptor of a host cell, thus enabling a host to resist coronavirus infection. Particularly, the present invention has good prevention and treatment effects on various mutant viruses.

ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF

NºPublicación:  EP4547711A2 07/05/2025
Solicitante: 
MODEX THERAPEUTICS INC [US]
US HEALTH [US]
Modex Therapeutics, Inc,
The United States of America, as represented by the Secretary, Department of Health and Human Services
CN_119836434_PA

Resumen de: WO2024007013A2

Disclosed are antigen binding antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptide complexes; and methods of using such polypeptide complexes.

SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-COVID-19 AGENTS

NºPublicación:  EP4547278A1 07/05/2025
Solicitante: 
ALLEXCEL INC [US]
Allexcel, Inc
MX_2024000185_A

Resumen de: MX2024000185A

There are provided improved amphiphilic comb polymers, comprising a hydrophilic backbone with regularly-spaced pendant hydrophobic moieties, having well-controlled molecular weights, structures, and end groups. The polymers self-assemble into core-corona nanoparticles in aqueous environments, which are capable of disrupting viral coat proteins, and which are capable of encapsulating antiviral drugs and prodrugs. Regularly-spaced targeting moieties optionally mediate the adherence of the nanoparticles to the viral coat. The compositions of the invention are useful as treatments for viral infection, including infections with SARS-CoV-2.

METHOD FOR TESTING DISEASE PROGRESSION TOWARD VASCULITIS OR TESTING RISK OF COVID-19 BECOMING SEVERE, TESTING KIT, COMPANION DIAGNOSTIC AGENT, AND TESTING MARKER

NºPublicación:  EP4549938A1 07/05/2025
Solicitante: 
A CLIP INST CO LTD [JP]
A-Clip Institute, Co., Ltd
EP_4549938_A1

Resumen de: EP4549938A1

Problem Provided are a new marker of disease activity useful for testing a diseased state of vasculitis or an exacerbation risk of COVID-19, and a means for testing a diseased state of vasculitis or an exacerbation risk of COVID-19 using the marker.Solution According to an aspect of the present invention, there are provided a method for testing a diseased state of vasculitis and a method for testing an exacerbation risk of COVID-19, the method including: detecting or quantifying, in a blood sample collected from a subject,(1) a No. 1 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 23 to 25 kDa, and/or(2) a No. 2 APOA2-like protein that causes an antigen-antibody reaction with a single chain variable region fragment consisting of an amino acid sequence set forth in SEQ ID NO: 1 and has a molecular weight of 16 to 20 kDa.

System and method for managing diagnostic testing and results

NºPublicación:  GB2635230A 07/05/2025
Solicitante: 
BHA GLOBAL LTD [MU]
BHA Global Ltd
GB_2635230_PA

Resumen de: GB2635230A

The present invention relates to a health and disease management system whereby a user performs a medical test on a device, whereafter the resulting test data is transmitted to an electronic database for verifying the test data and comparing the test data to benchmark data stored to derive one or more health and disease management recommendations. The device may be a self-test kit for a range of applications such as testing for COVID-19. The test data may include location data. The verification may authenticate the test results by comparing image data to an authenticity threshold value. Location data may be used to notify the user about a nearby health facility where treatment is available. A machine learning model may be trained to provide the disease management recommendations.

ANTI-SARS-COV-2 ANTIGEN BINDING POLYPEPTIDES, POLYPEPTIDE COMPLEXES AND METHODS OF USE THEREOF

Nº publicación: EP4547335A2 07/05/2025

Solicitante:

MODEX THERAPEUTICS INC [US]
US HEALTH [US]
Modex Therapeutics, Inc,
The United States of America, as represented by the Secretary, Department of Health and Human Services

CN_119948053_PA

Resumen de: AU2023301087A1

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

traducir